The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data.

Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments.

Key Timestamps

1. 04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management.
2. 06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status.
3. 10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release.
4. 13:15 – System errors vs. Use errors: How to identify root causes during summative studies.
5. 18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation.
6. 22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions.
7. 25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites.

Quotes

"The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller

"People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci Miller

Takeaways

1. Premeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements.
2. Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile.
3. Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur.
4. HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams.

References

1. ISO 14971: The global standard for the application of risk management to medical devices.
2. FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation.
3. Etienne Nichols: LinkedIn Profile

MedTech 101: URRA vs. uFMEA

Think of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts.

A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment.

Sponsors

Greenlight Guru: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk.

Feedback Call-to-Action

We want to hear from you! Do you have questions about your specific regulatory pathway or a topic you’d like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to podcast@greenlight.guru.

The conversation pivots to the technical and strategic nuances of "same device, different claims." Mike explains that if a device maintains the same design but utilizes different labeling or indications for use across borders, it is technically a different device in the eyes of regulators. This creates significant complexity for Quality Management Systems and post-market surveillance, particularly concerning reporting requirements for Class III (PMA) devices.

Finally, the duo explores the "trap of equivalency," where companies mistakenly assume that a CE Mark or other international approval guarantees a smooth path through the FDA. From differing consensus standards to the strategic use of OUS (Outside US) clinical data, the episode provides a roadmap for global players to synchronize their regulatory and reimbursement strategies early in the development lifecycle.

Key Timestamps

1. 01:45 - Challenging the assumption: Should you always launch outside the US first?
2. 04:12 - Defining the "International Company": Why every developer should think globally from day one.
3. 05:30 - The Labeling Trap: Why the same hardware with different claims is a different device.
4. 07:50 - Post-market surveillance nuances: Reporting OUS issues in a US PMA submission.
5. 11:15 - The "Sniff Test": Does a CE Mark actually help you with the FDA?
6. 12:40 - Leveraging Real-World Evidence (RWE) from international markets for US submissions.
7. 14:30 - The "Species Expansion" concept: Applying regulatory logic across different use cases.
8. 16:15 - Consensus Standards: Why the FDA might not recognize the "most current" version of a standard.
9. 20:00 - International Regulatory Strategy: Calculating the "lowest common denominator" for multi-country launches.
10. 25:20 - Using 100% OUS clinical data for FDA submissions: The three essential caveats.

Quotes

"If you’re marketing the same device—same design, same materials—but the labeling and claims are different in the EU versus the US, then technically, it is not the same device." - Mike Drues

"The regulatory logic is agnostic of the scenario. Whether it's a label expansion or a 'species expansion' from a dog to a human, the underlying logic remains the same." - Mike Drues

Takeaways

1. Sync Your Standards: Do not assume the FDA recognizes the same version of a standard (e.g., ISO 10993-1) as international bodies. Always verify via the CDRH Recognized Consensus Standards database.
2. Design for the "Lowest Common Denominator": Identify your top 3–5 target markets early and pool their requirements to avoid redundant benchtop or clinical testing.
3. Rethink Clinical Trials: While the FDA prefers domestic data, OUS data can be used if you can prove the patient population and user profiles (physicians/nurses) are representative of the US demographic.
4. Anticipate "Off-Label" Pressure: If you market a device in Canada with claims not yet approved in the US, be prepared for US clinicians to find that information online and ask for "anticipated off-label use."

References

1. FDA Recognized Consensus Standards Database: Essential tool for verifying which versions of international standards the FDA currently accepts.
2. Greenlight Guru QMS & EDC: Solutions for managing complex, multi-region quality systems and clinical data.
3. Etienne Nichols’ LinkedIn: Connect with the host for more MedTech insights.

MedTech 101: Label Expansion

Think of Label Expansion like a smartphone software update. The hardware (the phone) stays the same, but the update allows the phone to do something it couldn't do before—like a new photography mode. In MedTech, if you have a stent approved for use in the leg (the "old label") and you want to use that same stent in the heart, you apply for a "label expansion." You aren't changing the device; you're just proving it’s safe and effective for a new job.

Sponsors: Greenlight Guru

This episode is brought to you by Greenlight Guru. Navigating international waters requires a robust foundation. Greenlight Guru’s Quality Management Software (QMS) helps you maintain a "single source of truth" for your design history files and labeling, while their Electronic Data Capture (EDC) solution streamlines the collection of the clinical data you'll need to satisfy both the FDA and international regulators. Whether you are managing post-market surveillance for a PMA or running a multi-center global trial, Greenlight Guru has you covered.

Feedback Call-to-Action

We want to hear from you! Did this episode change your mind about your international launch strategy? Do you have a "culture shock" story from bringing a device to the US? Send your thoughts, reviews, or topic suggestions to podcast@greenlight.guru. We read every email and love providing personalized responses to our listeners.

Etienne and Ivanny explore the critical intersection of global regulatory bodies—such as the NMPA in China and the FDA in the US—and the necessity of a cohesive clinical evidence strategy. Ivanny emphasizes that for startups, understanding market-specific data requirements is not just a regulatory hurdle but a fundamental component of commercialization and investor conviction.

The discussion also dives into the "patient empowerment" movement, fueled by the convergence of wearables, AI, and at-home monitoring. Ivanny shares her bullish outlook on technologies that give patients control over their data, while acknowledging the tension this creates for physicians and the ongoing need for rigorous regulatory oversight to ensure safety and effectiveness.

Key Timestamps

1. [03:15] Global Regulatory Strategy: Insights into the NMPA (formerly CFDA) and why China requires in-country clinical evidence.
2. [07:42] Leveraging Data: How to run a single clinical trial to satisfy multiple global regulatory bodies.
3. [10:18] The At-Home Monitoring Shift: The rise of wearables and OTC testing in the wake of COVID-19.
4. [13:45] The "Data Gap": Addressing the friction between patient-gathered data and physician adoption.
5. [18:22] Investment Non-Negotiables: Why revenue-generating companies and clear regulatory classifications are key for MedSight Capital.
6. [23:10] Diligence and Deception: The importance of honesty regarding reimbursement codes and 510(k) vs. PMA paths.
7. [27:45] SPV vs. Hedge Fund Models: A breakdown of how Special Purpose Vehicles allow family offices to be nimble in MedTech.

Quotes

"FDA and NMPA, for example, are quite strict in clinical evidence coming from in-country... as a startup, you really need to understand can we run a single trial with multiple global sites to achieve clearance cohesively." - Ivanny Franklin

"I’m an advocate for [at-home monitoring]. I do think that’s the future. However, there is concern around what types of information should patients be receiving and how are they going to act on that information?" - Ivanny Franklin

Takeaways

1. Regulatory is the Roadmap: An investment is often "de-risked" based on the clarity of the regulatory path. If a founder cannot distinguish between a 510(k) and a PMA, it is a major red flag for investors.
2. Harmonize Your Trials: To achieve "economies of scale" in clinical evidence, work with consultants to design trials that meet the stringent requirements of both the FDA and international bodies like the NMPA early on.
3. Commercial Scalability over Hype: For revenue-generating companies, investors are less concerned with the "idea" and more focused on physician retention, training, and the cost of scaling the sales team.
4. Honesty in Reimbursement: Never "make up" or guess CPT codes. Investors utilize experts (like ex-FDA personnel) to pressure-test your reimbursement strategy during diligence.

References

1. NMPA (National Medical Products Administration): The primary regulatory body for China (formerly the CFDA).
2. NAMSA: A world-leading Medical Device CRO mentioned as Ivanny’s former professional home.
3. LSI (Life Science Intelligence): The upcoming conference mentioned where Etienne and Ivanny will speak on a panel.
4. Greenlight Guru: The preferred platform for QMS & EDC solutions to manage medical device quality and clinical data.
5. Etienne Nichols: Connect on LinkedIn.

MedTech 101: SPV (Special Purpose Vehicle)

Think of a Special Purpose Vehicle (SPV) like a "carpool" for investors. Instead of a massive bus (a Hedge Fund) that picks up everyone's money and decides where to go over several years, an SPV is a single car created for one specific trip—in this case, one specific company.

Investors put their money into the SPV, and the SPV makes one investment in one startup. This allows smaller investors or family offices to pool their resources together to act as one large "passenger" on a company's cap table.

Sponsors

This episode is brought to you by Greenlight Guru. Moving from a "service-based" model to an "outcome-based" model requires impeccable data and quality management. Greenlight Guru offers both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions designed specifically for the medical device industry. Whether you are gathering clinical evidence for an NMPA submission or scaling a revenue-generating product, Greenlight Guru helps you stay compliant and efficient.

Feedback Call-to-Action

We want to hear from you! Did this breakdown of investment vehicles help you? Do you have suggestions for future MedTech topics? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, and questions to podcast@greenlight.guru.

The conversation delves into the "mismatch" of the pediatric market: these devices require the same rigorous regulatory and quality standards as adult products but offer significantly lower financial upside due to smaller patient populations. This creates a barrier for investors and manufacturers, leaving clinicians and nurses to "work miracles" with tools that aren't always fit for purpose.

Despite these hurdles, Edwin shares an optimistic vision for the future. He discusses his initiative to build a collaborative network of experts—including regulatory consultants, testing houses, and grant writers—willing to provide pro-bono or at-cost support for pediatric startups. The goal is to create a streamlined regulatory roadmap that prioritizes patient safety without the prohibitive costs that currently stall innovation.

Key Timestamps

1. 00:45 – The "Pediatric Gap": Why pediatric devices have adult-level requirements but lower ROI.
2. 03:12 – Personal Insight: Edwin’s experience in the hospital and the "Guinness philosophy" of giving back.
3. 05:30 – The danger of adhesives and adapting adult materials for newborn skin.
4. 08:15 – Building a pediatric volunteer network: Testing houses and consultancies stepping up.
5. 11:40 – Regulatory Roadmaps: Navigating the age variability from premature infants to adolescents.
6. 14:50 – Off-label usage risks and the "mindset shift" required for manufacturers.
7. 18:25 – Micro-timestamp: The FDA’s Humanitarian Device Exemption (HDE) and P-Sub programs.
8. 21:10 – Real-world clinical friction: Alarm fatigue and sensor sensitivity in NICU settings.
9. 25:40 – The hidden costs: Manufacturing complexity, multiple SKUs, and low-volume production.

Quotes

"We need to give clinicians the correct tools to work their miracles. They don't want to use products off-label; they want devices actually designed for the children they are saving." - Edwin Lindsay

"If you have a pediatric project, there is a community behind you. We are breaking down the barriers of risk and cost because these babies deserve a chance." - Edwin Lindsay

Takeaways

1. Regulatory Flexibility: Utilize specific FDA pathways like the Humanitarian Device Exemption (HDE) and the Pediatric Submissions (P-Sub) program to gain early feedback and specialized guidance.
2. Collaborative Cost-Sharing: Seek out "altruistic" partners; many testing houses and manufacturers are willing to work at-cost or under different financial models for pediatric-specific innovations.
3. Design for Sensitivity: Pediatric innovation isn't just about miniaturizing adult tech—it requires solving unique issues like alarm fatigue and skin sensitivity (e.g., non-damaging adhesives).
4. Workflow Integration: Engage the "head nurse" early in R&D to ensure the device fits into the high-stress environment of a pediatric ward without adding to clinical fatigue.

References

1. FDA HDE Program: A regulatory pathway for devices intended for diseases or conditions that affect small populations.
2. Greenlight Guru: The industry-leading platform for QMS & EDC solutions, helping MedTech companies maintain compliance while accelerating pediatric product development.
3. Etienne Nichols on LinkedIn: Connect with Etienne for more MedTech insights.

MedTech 101: Off-Label Use

In the medical device world, "Off-Label" means using a device for a purpose, or on a patient population (like infants), that the FDA has not officially cleared.

Think of it like this: Imagine you have a high-tech hiking boot designed for a grown man, but you have to put it on a toddler because no one makes toddler-sized hiking boots. You might be able to make it stay on with extra socks and tape, but it won't support the child’s foot correctly and might cause them to trip. In pediatrics, doctors often have to "tape the boot" because specialized devices simply don't exist.

Feedback Call-to-Action

We want to hear from you! Are you working on a pediatric breakthrough, or have you faced challenges in this niche market? Whether you have a topic suggestion or a question for Edwin, send us an email at podcast@greenlight.guru. We read every message and pride ourselves on providing personalized responses to our community.

Sponsors

This episode is brought to you by Greenlight Guru. Navigating the complex regulatory landscape of pediatric devices requires a robust foundation. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions are specifically designed to help MedTech innovators manage risk and clinical data with precision. Whether you are a one-person startup or a global entity, Greenlight Guru helps you get safe, effective technology to patients faster.

Dr. Katzenmeyer-Pleuss highlights the significance of the upcoming ISO 10993-1:2025 standard and its renewed emphasis on life cycle-based risk assessments. She explains how the transition between global markets—particularly between the EU and the US—can lead to unexpected FDA deficiencies when manufacturers rely on justifications that worked for notified bodies but do not meet more stringent FDA testing expectations for reusable or in situ curing devices.

The discussion concludes with actionable advice on early design decisions, such as narrowing down material suppliers and reprocessing options to reduce testing burdens. They also explore the critical need for cross-functional communication and quality system integration to ensure that learnings from one project or regulatory interaction are captured and applied across a company’s entire portfolio.

Key Timestamps

1. 01:45 – Introduction of Dr. Kristy Katzenmeyer-Pleuss and the mission of KP Medical Device Consulting.
2. 04:12 – Defining the Medical Device Life Cycle: Concept to decommissioning and the "hidden" phases in between.
3. 05:30 – ISO 10993-1:2025: The impact of the new biological evaluation standard on risk-based approaches.
4. 09:15 – Global Regulatory Discrepancies: Why a device approved in Europe might face hurdles at the FDA regarding "worst-case" testing.
5. 13:40 – Reusable Devices & Reprocessing: Managing the "permutation explosion" of cleaning agents and sterilization cycles.
6. 17:22 – Early Design Decisions: How limiting options in the IFU can significantly decrease your regulatory testing burden.
7. 21:05 – In Situ Curing Devices: The unique testing challenges of materials that change states during use.
8. 25:10 – Quality System Integration: Strategies for linking regulatory deficiencies and materials across multiple projects.

Quotes

"The life cycle is really the concept of the medical device from when it’s a concept all the way through to the end where you are disposing or decommissioning... shelf life and transport are steps that usually don’t get a lot of focus, but they are very important." - Dr. Katzenmeyer-Pleuss

"You might have one device where literally they don’t ask these questions at all, and then other times they’re very, very picky... the longer you go in that process, the harder it is to pivot without spending a lot of time and money." - Dr. Katzenmeyer-Pleuss

Takeaways

1. Front-load Risk Assessments: Don’t wait for FDA deficiencies to consider how shelf life or reprocessing affects device safety; integrate these into the biological evaluation plan from day one.
2. The "Worst-Case" Strategy: When designing testing protocols for reusable devices, aim for a "worst-case" scenario that covers future iterations or additional suppliers to avoid redundant, expensive re-testing.
3. Standardize Your IFU Early: Providing users with infinite cleaning or sterilization options creates an exponential increase in testing requirements; narrow these down to the essentials to streamline market entry.
4. Break the Silos: Use your QMS to link specific material risks or regulatory feedback across different project teams so that knowledge isn't lost when personnel leave.

References

1. ISO 10993-1:2025: The updated international standard for the biological evaluation of medical devices within a risk management process.
2. Etienne Nichols on LinkedIn: Connect with the host for more MedTech insights.

MedTech 101: In Situ Curing

In this episode, Dr. Katzenmeyer-Pleuss mentions In Situ Curing. Think of this like a medical-grade "liquid bandage" or dental filling. The device starts as a liquid or gel and is applied to the body, where it then hardens into a solid "in the spot" (in situ).

From a regulatory standpoint, this is complex because you aren't just testing one device; you have to test the safety of the liquid, the safety of the solid, and any chemicals released during the hardening process. It is essentially three devices in one when it comes to testing.

Sponsors

This episode is brought to you by Greenlight Guru. When navigating the complex life cycle of a medical device—from the initial risk assessments discussed today to post-market surveillance—you need a unified system. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions work together to ensure your data is linked, your testing is documented, and your clinical trials are seamless. By connecting your quality and clinical data, you can avoid the "disjointed" project management pitfalls Etienne and Kristy discussed.

Feedback Call-to-Action

What are your biggest hurdles in managing the full medical device life cycle? We want to hear from you. Whether it's a specific regulatory challenge or a topic suggestion for a future guest, send your thoughts to podcast@greenlight.guru. We read every email and pride ourselves on giving personalized responses to our MedTech community.

Rollins explains that modern medical devices are far more complex than the metal and hard plastics of the past. With the rise of degradable materials, coatings, and nanomaterials, traditional animal testing often fails to provide the best science. The new standard introduces critical concepts such as biological risk estimation, foreseeable misuse, and a comprehensive lifecycle evaluation that looks beyond "time zero" safety.

The duo also discusses the practical implications for manufacturers, including the controversial requirement to evaluate biocompatibility at the end of a product's lifecycle—a particular challenge for reprocessed devices. Rollins provides insider knowledge on the US’s stance on the revision, the timeline for FDA recognition, and how companies can leverage biological equivalence to potentially reduce their testing burden.

Key Timestamps

1. 01:45 – The shift from "checkboxing" to a risk-based approach.
2. 03:10 – The rapid timeline of the 2025 revision and the influence of ISO 14971.
3. 04:22 – Lifecycle Evaluation: Assessing safety beyond the "brand new" state.
4. 06:50 – Chronic toxicity vs. acute reactions: Why front-end evaluation matters.
5. 08:15 – Foreseeable Misuse: When doctors use scopes outside their intended anatomy.
6. 12:10 – The concept of Bioequivalence: Using existing data to justify reduced testing.
7. 13:45 – Breakthrough: The removal of material-mediated pyrogenicity testing for known materials.
8. 15:30 – Why the US voted "No" on the current draft: A call for better guidance.
9. 18:50 – Notified Bodies and MDR: The 2025 version as "State of the Art."
10. 21:15 – Practical chemistry tests for aging polymers (DSC, GPC, FTIR).
11. 25:40 – Advice for small vs. large companies on building material databases.

Quotes

"The testing that we developed back in the 50s and 60s actually doesn't really work the best with some of these complex devices... we've been moving the standard away from what we call checkboxing." - Thor Rollins

"I only say that expensive tests always impact innovation. We don't want to over-test, but we want to do the right tests." - Thor Rollins

Takeaways

1. Lifecycle is the New Frontier: You must now evaluate biocompatibility throughout the product's life, especially for reprocessed devices that may degrade after hundreds of cleaning cycles.
2. Foreseeable Misuse is a Regulatory Reality: If it is likely a clinician will use your device off-label (e.g., a pulmonary scope used in vascular applications), you must account for that biological risk in your assessment.
3. Leverage Bioequivalence: Stop testing the same stainless steel or titanium repeatedly. Use existing data and internal databases to justify "no testing" for known materials and processes.
4. Partner with Expertise: Because the standard is less prescriptive and more risk-based, the quality of your Biological Evaluation Plan (BEP) depends entirely on the expertise of the person writing it.
5. Chemistry over Animals: Whenever possible, use chemistry (Extractables & Leachables) and in vitro methods to replace legacy animal tests, as the 2025 revision officially begins to phase out certain animal-based requirements.

References

1. ISO 10993-1:2025: The primary global standard for the biological evaluation of medical devices.
2. ISO 14971: The standard for the application of risk management to medical devices, now heavily integrated into 10993-1.
3. Nelson Labs: The laboratory where Thor Rollins leads biocompatibility strategy.
4. Etienne Nichols: Connect with Etienne on LinkedIn.

MedTech 101: Bioequivalence

Think of bioequivalence like buying a generic medication versus a brand-name one. If you know the ingredients (materials) and the way they are manufactured (processes) are identical to a device that has already been proven safe on the market, you shouldn't have to re-run expensive, time-consuming tests. In MedTech, this means showing that your "New Device B" is biologically the same as your "Proven Device A" because they use the same grade of titanium and the same sterilization method.

Sponsors

This episode is brought to you by Greenlight Guru. As the industry shifts toward a risk-based approach as seen in ISO 10993-1:2025, having a centralized source of truth is vital. Greenlight Guru's QMS (Quality Management System) allows you to integrate risk management directly into your design process, while their EDC (Electronic Data Capture) solution helps you gather the clinical evidence needed to prove long-term safety. When your risk assessments and clinical data live in the same ecosystem, "state of the art" compliance becomes a standard, not a struggle.

Feedback Call-to-Action

We want to hear from you! How is your team preparing for the 2025 revision of ISO 10993-1? Are you concerned about the lifecycle evaluation requirements? Send your thoughts, questions, or topic suggestions to podcast@greenlight.guru. We read every email and love providing personalized responses to our community.

The conversation examines the critical differences between 510(k), De Novo, and PMA pathways regarding manufacturing requirements. While a 510(k) submission may not strictly require detailed manufacturing information at the time of filing, Mike explains why companies must remain audit-ready from the moment they register their establishment with the FDA. The discussion clarifies the timing of registration and the "radar" companies enter once they become commercially active.

Finally, the dialogue focuses on a "triage" approach for resource-constrained startups. By prioritizing Design Controls and Risk Management during early development, teams can remain compliant and ethical without over-investing in post-market systems, such as complaint handling, before they have a product on the market. Mike warns against the dangers of "copy-and-paste" quality systems, urging manufacturers to use professional judgment to tailor their processes to their specific technology.

Key Timestamps

1. 00:00 - Introduction to QMS requirements and guest Mike Drues.
2. 03:45 - The core sections of a QMS according to the Quality System Regulation.
3. 05:12 - Why the QSR list is a starting point, not a stopping point.
4. 08:20 - Regulatory vs. Ethical vs. Economical: The three legs of the medical device stool.
5. 10:30 - Do you need a full QMS for 510(k) vs. PMA submissions?
6. 13:15 - Understanding the timing and strategy for FDA Establishment Registration.
7. 15:40 - The Triage Approach: Which QMS sections matter most during early development?
8. 19:00 - The dangers of boilerplate SOPs and non-specific quality manuals.

Quotes

"This is a starting point. This is not a stopping point... Use your own good judgment." — Mike Drues

"The goal is not really to build a museum of SOPs; the goal is a quality management system that teams will actually use." — Etienne Nichols

Takeaways

1. Prioritize the Big Four: During the development phase, focus your limited resources on Design Controls, Risk Management, Document Control, and Supplier Quality Management.
2. Understand Pathway Nuances: While 510(k) submissions don't require manufacturing details, you must be fully compliant and ready for inspection once your establishment is registered and the product is launched.
3. Avoid Boilerplate SOPs: Quality systems must be specific to your organization. Including irrelevant device types or procedures in your QMS is a significant red flag for FDA inspectors.
4. Strategic Registration: Register your establishment 60–90 days before your planned commercial launch to manage costs and stay off the FDA inspection radar until necessary.
5. The Preamble is Key: Read the preamble of the QSR to understand the "why" behind the regulations, which allows for better justification of your quality decisions during an audit.

References

1. FDA Design Control Guidance (1997): A foundational document for medical device engineering and documentation.
2. FDA Establishment Registration: Guidance on the timing and requirements for small business fee waivers.
3. Etienne Nichols LinkedIn: https://www.linkedin.com/in/etiennenichols/

MedTech 101 Section

Concept: The Quality Management System (QMS) Think of a QMS like a pilot’s pre-flight checklist. You don't just "wing it" when you get into a cockpit; you have a documented process to ensure the engine is working, the fuel is full, and the wings are clear. For a small plane (a low-risk Class I device), your checklist is shorter and simpler. For a commercial jumbo jet (a high-risk Class III device), the checklist is massive and detailed. However, the goal for both is identical: ensuring the passengers (the patients) arrive safely at their destination through a repeatable, controlled process.

Sponsors

This episode is brought to you by Greenlight Guru. The subject of right-sizing your quality system is exactly why Greenlight Guru offers both QMS and EDC solutions. Their Ultralight eQMS is designed specifically for fast-moving, product-led teams who need a flexible, compliant system without the overhead of a "museum of SOPs." Whether you are in early-stage R&D or preparing for a global launch, Greenlight Guru provides the tools to keep your quality and clinical data connected and audit-ready.

Feedback Call-to-Action

We want to hear from you! What are the biggest hurdles your team faces when scaling your quality system? Send your feedback, reviews, and topic suggestions to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our listeners.

Ashkon breaks down the specific failure modes unique to generative models, most notably "hallucinations." He explains how these outputs can appear legitimate while being factually incorrect, and explores the cascading levels of risk this poses. The discussion moves from simple credibility issues to severe safety concerns when AI-generated data is used in critical clinical decision-making without proper guardrails.

The episode concludes with a forward-looking perspective on how validation is shifting. Ashkon argues that because GenAI behavior is statistical rather than deterministic, traditional pre-market validation is no longer sufficient. Instead, a robust quality framework must include continuous post-market surveillance and real-time independent monitoring to ensure device safety and effectiveness over time.

Key Timestamps

1. 01:45 - Introduction to MD&M West and the "AI Guy for SaMD," Ashkon Rasooli.
2. 04:12 - Defining Generative AI: How it differs from traditional machine learning and image recognition.
3. 06:30 - Hallucinations: Exploring failure modes where AI creates plausible but false data.
4. 08:50 - The Autonomy Scale: Applying standard 34971 to determine the level of human supervision required.
5. 12:15 - Regulatory Gaps: Why no generative AI medical devices have been cleared by the FDA yet.
6. 15:40 - Safety by Design: Using "independent verification agents" to monitor AI outputs in real-time.
7. 19:00 - The Shift to Post-Market Validation: Why 90% validation at launch requires 10% continuous monitoring.
8. 22:15 - Comparing AI to Laboratory Developed Tests (LDTs) and the role of the expert user.

Quotes

"Hallucinations are just a very familiar form of failure modes... where the product creates sample data that doesn't actually align with reality." - Ashkon Rasooli

"Your validation plan isn't just going to be a number of activities you do that gate release to market; it is actually going to be those plus a number of activities you do after market release." - Ashkon Rasooli

Takeaways

1. Right-Size Autonomy: Match the AI’s level of independence to the risk of the application. High-risk diagnostic tools should have lower autonomy (Level 1-2), while administrative tools can operate more freely.
2. Implement Redundancy: Use a "two is one" approach by employing an independent AI verification agent to check the primary model’s output against safety guidelines before it reaches the user.
3. Narrow the Scope: To reduce hallucinations, limit the AI's task breadth. A model asked to write a specific security requirement is more reliable than one asked to generate an entire Design History File (DHF).
4. Prioritize Detectability: Design UI/UX features that provide the sources or "basis" for an AI's answer, allowing human users to verify the data and catch errors more easily.
5. Continuous Surveillance: Accept that pre-market validation cannot cover all statistical outcomes; establish a post-market "watchtower" to monitor for performance shifts and user feedback trends.

References

1. ISO 14971: The standard for the application of risk management to medical devices.
2. AAMI TIR34971: Guidance on the application of ISO 14971 to machine learning in medical devices.
3. IEC 62304: Medical device software lifecycle processes.
4. Etienne Nichols: LinkedIn Profile

MedTech 101: The Autonomy Scale

Think of the Autonomy Scale like the driver-assist features in a car.

1. Level 1 is like a backup camera: It gives you data, but you are still 100% in control of the steering and braking.
2. Level 5 is a fully self-driving car where you can sleep in the back seat.

In MedTech, most generative AI is currently aiming for Level 2 or 3, where the AI suggests a "route" (like a diagnosis or a draft report), but a human "driver" (the doctor or engineer) must keep their hands on the wheel and verify every turn.

Sponsors

This episode is brought to you by Greenlight Guru. Whether you are navigating the complexities of generative AI or traditional hardware, Greenlight Guru offers the only specialized Quality Management System (QMS) and Electronic Data Capture (EDC) solutions designed specifically for the medical device industry. By integrating your quality processes with clinical data collection, Greenlight Guru helps you move from "check-the-box" compliance to true quality.

Feedback Call-to-Action

We want to hear from you! How is your team implementing AI in your workflow? Do you have questions about the shifting regulatory landscape? Send your thoughts, reviews, or topic suggestions to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our community of MedTech movers and shakers.

The conversation centers on the concept of "SOS moments," which Dr. Hoffmann defines as those critical points of distress or crisis that occur in both personal lives and product development. By applying her CEC framework—Curiosity, Empathy, and Connection—leaders can transform these high-pressure moments into stories of strength. This approach is particularly vital in MedTech, where the ultimate goal is to serve patients during their own most vulnerable SOS moments.

Etienne and Jenny also explore the intersection of human leadership and emerging technology. While AI continues to streamline technical workflows, Dr. Hoffmann argues that human empathy and curiosity remain irreplaceable assets for innovation. The episode concludes with a practical look at the return on investment (ROI) for "opening up," demonstrating how personal connection leads to higher quality products, better team retention, and the resilience needed to survive the "messy middle" of product development.

Key Timestamps

1. 00:00 - Introduction of Dr. Jenny Hoffmann and her background in MedTech and innovation.
2. 01:28 - Motivation for writing Open Up: Scaling impact through vulnerable storytelling.
3. 04:23 - The shift from the "perfectly composed" leader to the vulnerable leader.
4. 05:45 - Dr. Hoffmann’s personal origin story: Being one of the first IVF babies in the U.S.
5. 08:30 - Listening to the "whisper" and the courage required to respond to inner intuition.
6. 10:14 - The ROI of Vulnerability: How personal connection drives higher quality and team motivation.
7. 14:39 - Defining SOS moments: Turning distress signals into leadership strengths.
8. 18:42 - The CEC Method: Breaking down Curiosity, Empathy, and Connection.
9. 20:25 - AI in MedTech: Why human empathy is the one thing machines cannot replace.
10. 25:57 - Strategic Sharing vs. Oversharing: How to lead by example without losing professional boundaries.
11. 28:52 - The power of storytelling for engineers and data-driven professionals.

Quotes

"The leader is the first one to step out on the bridge that no one’s sure if they want to cross. You paint that vision of the bridge, and then you’re the first one to step out on it." - Dr. Hoffman

"If we can put empathy first and think about how we are each a patient first... then we can uncover the real needs to solve. Then we can be more innovative." - Dr. Hoffman

Takeaways

1. The CEC Framework: Use Curiosity to open the mind, Empathy to open the heart, and Connection to drive outsized results in technical teams.
2. Embrace SOS Moments: View professional crises or personal struggles as distress signals that, when analyzed with curiosity, provide the data needed to build resilience.
3. Human-Centric AI Strategy: Leverage AI for efficiency and data processing, but double down on human empathy to solve complex patient needs that machines cannot grasp.
4. Strategic Vulnerability: Sharing personal stories is a leadership skill. Start small by sharing "Monday morning" anecdotes before moving to deeper personal values to build team trust.
5. The Mission Dimension: In MedTech, motivation isn't just about time and effort; it is about the "third dimension" of mission-driven impact that keeps teams moving through the "messy middle" of a project.

References

1. Open Up: Step Into the Leader You Are Meant to Be by Dr. Jenny Hoffmann – The core book discussed, focusing on vulnerable leadership.
2. New England Medical Innovation Center (NEMIC) – Where Dr. Hoffmann serves as Executive Director.
3. Sure Footing Consulting – Dr. Hoffmann’s leadership and strategy firm.
4. Etienne Nichols LinkedIn – Connect with the host.

MedTech 101: SOS Moments

In a medical context, an SOS is a distress signal indicating an immediate need for help. In leadership, Dr. Hoffmann uses "SOS moments" as an acronym for "Story of Strength" and an analogy for those times when you feel overwhelmed, fearful, or hit a major roadblock in a project (like a failed regulatory submission or a budget crisis), it can also be a moment to look back on and learn from.

Just as a clinician responds to a patient’s distress signal by diagnosing the underlying issue, a MedTech leader should respond to their own "emotional SOS" by using the CEC Method.

Sponsors

This episode is brought to you by Greenlight Guru. In the medical device industry, the "messy middle" of development is often where teams lose momentum. Greenlight Guru helps you stay focused on your mission by providing the only dedicated MedTech Lifecycle Excellence platform. Their QMS (Quality Management System) ensures your documentation is always audit-ready, while their EDC (Electronic Data Capture) solution streamlines clinical data management. By integrating quality and clinical data, Greenlight Guru allows leaders to spend less time on paperwork and more time on the vulnerable, innovative leadership discussed in today's episode.

Feedback Call-to-Action

We want to hear from you. How do you balance vulnerability with technical authority in your leadership role? Have you experienced an "SOS moment" that changed your career path? Please send your thoughts, reviews, or suggestions for future topics to podcast@greenlight.guru. We read every email and look forward to providing personalized responses to our listeners.

The discussion also touches on the challenges and opportunities in validating and regulating AI within MedTech, highlighting real-world applications and predicting future trends.

"Validation of AI tools in MedTech requires a staged adoption to build confidence due to the inherent uncertainty in AI outcomes." - Ashkon Rasooli

• 00:00 - Introduction to AI in MedTech
• 05:15 - Discussing AI's deterministic vs. statistical nature
• 12:30 - AI in diagnostics: Radiology, Cardiology, and Neurology
• 20:45 - Wearable health monitors and patient-driven health data
• 28:10 - The role of AI in medical device operations and manufacturing
• 35:00 - AI at the point of care: Enhancing patient and clinician experience
• 42:15 - Regulatory challenges and the future of AI in healthcare

Key Takeaways:

1. Latest MedTech Trends:

• The integration of AI in diagnostics is growing, particularly in radiology, cardiology, and neurology, aiding in more accurate and quicker diagnoses.
• Wearable health monitors are empowering patients to take control of their health data, leading to personalized healthcare solutions.

2. Practical Tips for MedTech Enthusiasts:

• Stay informed about the latest AI advancements and regulatory guidelines to leverage AI effectively in MedTech.
• Consider the ethical implications and ensure bias mitigation in AI model training and deployment.

3. Predictions for the Future:

• Increased adoption of AI across various healthcare sectors, including surgery and patient care management.
• Evolution of regulatory frameworks to better accommodate and oversee AI-driven medical devices.

References:

• Ashkon Rasooli on LinkedIn
• ashkon@engeniussolutions.com
• Engenius Solutions
• AFDO/RAPS Working Group
• Etienne Nichols on LinkedIn

Sponsors:

This episode is brought to you by Greenlight Guru, a comprehensive solution designed to streamline MedTech product development and ensure regulatory compliance. Discover how Greenlight Guru can accelerate your projects at www.greenlight.guru

Share your thoughts and questions with us at podcast@greenlight.guru

Key Timestamps:

• [00:00:50] Introduction to Jennifer Mascioli-Tudor and her extensive background in the MedTech industry.
• [00:03:30] Jennifer's origin story in quality and regulatory roles.
• [00:07:15] The pivotal learning moments in quality management and regulatory affairs.
• [00:10:45] Strategies for influencing business leaders and the importance of storytelling in quality and regulatory roles.
• [00:16:30] The significance of human factors in product design and learning from end-user feedback.
• [00:21:50] Project management skills for quality and regulatory professionals.
• [00:25:20] The concept of 'design freeze' in the MedTech space and its impact on product development.
• [00:29:55] Jennifer's insights on agility and adaptability in building a quality management system.

Quotes:

• "A really good quality and regulatory professional needs to have really good project management skills." - Jennifer Mascioli-Tudor
• "It's not just about the design and about the product. It's about everything ancillary that feeds into that finished medical device." - Jennifer Mascioli-Tudor

MedTech Trends:

1. An emphasis on proactive quality management to ensure patient safety and product efficacy.
2. The rising importance of human factors and user-centered design in medical device development.
3. The shift towards integrating software and digital solutions in medical devices.

Practical Tips:

1. Quality and regulatory professionals should hone their project management skills.
2. Communication and storytelling are key in influencing business decisions and leadership.
3. Always present solutions and alternatives when addressing compliance challenges.

References:

• JMT Compliance Consulting
• Jennifer Mascioli-Tudor on LinkedIn
• Etienne Nichols on LinkedIn
• Greenlight Guru’s platform for Quality Management & Clinical Investigations

Questions for the Audience:

• Discussion: "How do you envision MedTech changing the landscape of healthcare in the next decade?"

Feedback:

• Love the episode? Have suggestions or topics you’d like to hear about? Email us at podcast@greenlight.guru and leave a review on iTunes!

Sponsors:

This episode is brought to you by Greenlight Guru, the only quality management software designed specifically for the medical device industry. Streamline your process and foster innovation with Greenlight Guru’s intuitive platform!

The conversation dives deep into the "Great Rewiring" of the medical device industry. Michelle outlines how we have moved past the initial phase of AI skepticism and "AI fatigue" into a period of hyper-acceleration. With the introduction of the FDA’s ELSA and the implementation of the EU AI Act, the industry has reached a point where AI is no longer a side project but a fundamental requirement for operational longevity.

Finally, the episode provides a roadmap for both organizations and individual contributors. Michelle introduces her "Holy Trinity" framework for AI implementation—Data, Workflow, and Agents—and explains why the next two years will be defined by the "Invisible Colleague" or AI copilot. For junior professionals, the message is clear: knowledge is now a commodity, and the real value lies in the ability to ask high-quality, strategic questions.

Key Timestamps

• 00:00 – Introduction and Michelle Wu’s background in MedTech and AI.
• 03:45 – A founder’s perspective: Michelle’s personal experience in the OR seeing her clients' devices.
• 08:12 – The 2025 Inflection Point: FDA ELSA, EU AI Act, and global AI expectations.
• 11:50 – From billable hours to value-based output: How AI is disrupting the consulting business model.
• 15:35 – Micro-timestamp: 2026 Predictions. The shift toward universal AI Copilots and Agents for every MedTech role.
• 18:22 – The Holy Trinity of AI: Breaking down Data Layers, Workflow Automation, and AI Agents.
• 22:10 – Case Study: How a top-tier MedTech company automated 17,000 quality and regulatory tasks.
• 27:45 – The 56.8% Salary Premium: Why AI literacy is the most important skill for young RAQA professionals.
• 31:15 – Shifting from memorization to "Clarity of Mind" and high-quality inquiry.

Quotes

"Knowledge is a commodity now. Previously, regulatory consultants or professionals stood out by their knowledge. Now, with AI leveling the field, the capability lies in those who can ask high-quality questions." - Michelle Wu, Nyquist AI

Takeaways

• AI Literacy is a Financial Multiplier: LinkedIn data shows that non-engineering knowledge workers with AI literacy can command a salary premium of up to 56.8%.
• The 80/20 Rule of Automation: Approximately 80% of current RAQA tasks are tedious, manual, or administrative. Successful teams are using AI to automate that 80%, allowing humans to focus on the 20% that is strategic and high-value.
• The Three-Layer AI Strategy: To effectively implement AI, companies should look at the Data Layer (intelligence), the Workflow Layer (automation of specific tasks), and the Agent Layer (autonomous "employees").
• Value-Based Billing: As AI reduces the time required for regulatory submissions and gap analyses, the industry is moving away from the "billable hour" toward pricing based on the value and quality of the output.

References

• Nyquist AI: Michelle Wu’s platform specializing in global regulatory intelligence and AI-driven workflow automation for MedTech.
• FDA ELSA: The FDA’s internal AI tool that marked a significant shift in the agency's embrace of the technology.
• IMDRF GMLP: Good Machine Learning Practice guidelines for AI-enabled medical devices.
• EU AI Act: The first comprehensive legal framework for AI, affecting MedTech compliance timelines.
• Etienne Nichols: Connect with Etienne on LinkedIn.

MedTech 101: AI Agents vs. AI Chatbots

While many people are familiar with AI Chatbots (like the early versions of ChatGPT), the industry is moving toward AI Agents.

Think of a Chatbot like a very smart encyclopedia. You ask it a question about a 510(k) submission, and it gives you information.

An AI Agent, however, is like an AI Intern. It doesn't just give you information; it performs a multi-step task. For example, you can tell an Agent to "find the three most relevant predicates for this new device, summarize their 510(k) summaries, and draft a gap analysis table." The Agent "thinks" through the steps and delivers a finished product, not just a response.

Sponsors

This episode is brought to you by Greenlight Guru. As Michelle and Etienne discussed, the future of MedTech is driven by data and efficiency. Whether you are navigating the complexities of the EU AI Act or scaling your R&D, Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions provide the structured data foundation necessary to leverage AI effectively. By integrating quality and clinical data, Greenlight Guru helps you move from "reactive" compliance to "proactive" innovation.

Feedback Call-to-Action

We want to hear from you! How is your team currently leveraging AI in your regulatory or quality workflows? Are you feeling the "AI fatigue," or are you seeing the "salary premium" Michelle mentioned?

Send your thoughts, guest suggestions, or specific questions to podcast@greenlight.guru. Etienne personally reads and responds to listener feedback, and we would love to feature your insights in a future episode.

The episode debunks the myth that familiar quality documents like the DHF, DMR, and DHR are being eliminated. While the specific terms are removed from the regulation's language, their substance is retained and mapped to new, ISO-aligned conceptual requirements: the Device Master Record (DMR) becomes the Medical Device File (MDF), the Design History File (DHF) becomes the Design and Development File (DDP), and the Device History Record (DHR) is captured in the Batch or Lot Record. The host emphasizes that internal documents can retain the old terminology, provided a clear regulatory mapping is established.

Crucially, compliance requires more than just an ISO 13485 certificate. Two major philosophical shifts must be addressed: the explicit requirement for integrating lifecycle risk management as the DNA of the entire QMS, and the loss of the audit privilege, which makes internal audit reports, supplier audit reports, and management review records inspectable regulatory evidence. Furthermore, manufacturers must comply with retained, US-specific requirements under the QMSR's prevalence rule, especially concerning mandatory record content (§ 820.35) and specific labeling and packaging controls (§ 820.45).

Key Timestamps

1. [0:50] QMSR: The biggest shakeup to US quality requirements since 1996.
2. [2:00] Effective Date: February 2, 2026—the clock is ticking.
3. [2:42] The Goal: Harmonization with ISO 13485:2016 to reduce redundancy for global manufacturers.
4. [3:50] Myth 1 Busted: The FDA is eliminating the DHF, DMR, and DHR (Documentation Dissolution).
5. [5:10] Terminology Shift: DMR > Medical Device File (MDF, ISO 13485 Clause 4.2.3).
6. [6:30] Terminology Shift: DHF > Design and Development File (DDP, ISO 13485 Clause 7.3.10).
7. [7:40] Terminology Shift: DHR > Batch or Lot Record (ISO 13485 Clause 7.5.1).
8. [8:40] The Practical Takeaway: Internal naming is fine, but regulatory mapping is mandatory.
9. [10:30] Critical Shift 1: Risk Management is the DNA of the QMS—Explicitly required across all clauses.
10. [13:00] Critical Shift 2: Loss of the Audit Privilege—Internal audit and management review records are now inspectable.
11. [17:00] Critical Shift 3: Retained FDA Specifications (Prevalence Rule).
12. [17:35] Retained Req. A: Mandatory Record Keeping Content (21 CFR Part 820.35)—UDI/UPC in complaint/service records.
13. [19:00] Retained Req. B: Extended Record Retention Period (Device life, no less than two years).
14. [20:10] Retained Req. C: Specific Labeling and Packaging Controls (21 CFR Part 820.45)—Inspection for accuracy.
15. [22:00] Immediate Action Plan: Gap analysis and restructuring to the new terminology.

Quotes

"Your internal audit reports, your management review minutes, if you were expecting to keep those shielded from any outside eyes, they are now inspectable regulatory evidence." - Etienne Nichols

Takeaways

1. Mandatory Regulatory Mapping: Manufacturers must conduct a thorough mapping exercise to ensure their existing DMR, DHF, and DHR content fulfills the new requirements of the Medical Device File (MDF), Design and Development File (DDP), and Batch/Lot Records, respectively.
2. Embed Lifecycle Risk Management: The QMSR requires a holistic, lifecycle approach to risk management, making it an explicit core component of all QMS clauses (e.g., supplier controls, design and development), moving beyond isolated, perfunctory steps.
3. Prepare for Full Documentation Exposure (Regulatory): Recognize that the former privilege is gone; internal audit reports, supplier audit reports, and management review records are now subject to routine FDA inspection. Draft these documents with the utmost rigor and awareness of their new status as regulatory evidence.
4. Confirm Compliance with FDA Retained Sections: ISO 13485 certification is not enough. You must address the US-specific requirements retained under the prevalence rule, particularly the mandatory inclusion of UDI/UPC in complaint records (§ 820.35) and the strict labeling/packaging inspection controls (§ 820.45).
5. Transition is Immediate: The compliance date of February 2, 2026, is a hard deadline. Proactive gap analysis, process restructuring, and staff training based on the QMSR's requirements and the FDA's preamble are essential for uninterrupted market access.

References

1. ISO 13485:2016: The international Quality Management System standard for medical devices incorporated by reference into the QMSR.
2. 21 CFR Part 820 (New QMSR): The revised Code of Federal Regulations that replaces the QSR, incorporating ISO 13485 and retaining US-specific supplemental provisions.
3. 21 CFR Part 820.35 (Control of Records): Retained section requiring specific content, like UDI/UPC, for complaint and service records.
4. 21 CFR Part 820.45 (Device Labeling and Packaging Controls): Retained section requiring documented procedures for inspecting labeling and packaging accuracy.
5. QMSR Preamble: The FDA's detailed commentary and response to comments, which is crucial for understanding the Agency's interpretive thinking behind the new rule.
6. Etienne Nichols' LinkedIn: https://www.linkedin.com/in/etienne-nichols/

MedTech 101 Section

What is the "Prevalence Rule"?

The Prevalence Rule is a key concept in the new Quality Management System Regulation (QMSR) that clarifies which set of rules takes priority. Since the FDA is incorporating the international standard ISO 13485:2016 by reference, a conflict could arise between the ISO standard and existing U.S. law. The Prevalence Rule dictates that in any area of conflict, the U.S. Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations (like those retained in 21 CFR Part 820) will always supersede the ISO 13485 requirement. Think of it like a recipe: ISO 13485 is the main set of instructions, but the retained 21 CFR sections are non-negotiable, mandatory additions or modifications that must be followed regardless of what the main instructions say. This is why mere ISO certification does not guarantee QMSR compliance.

Sponsors

This episode is brought to you by Greenlight Guru. As the medical device industry faces the significant shift to the QMSR, your QMS needs to be audit-ready and easy to update. Greenlight Guru offers an all-in-one MedTech lifecycle excellence platform with specialized QMS and EDC solutions. Our electronic Quality Management System (eQMS) is built to facilitate the traceability and document control necessary to manage the new ISO-aligned terminology and retained FDA...]]>The FDA's new Quality Management System Regulation (QMSR), which replaces the 21 CFR Part 820 Quality System Regulation (QSR) and incorporates ISO 13485:2016 by reference, represents a significant harmonization effort in the medical device industry. While viewed by some as a mere streamlining, the change is mandatory, with an effective and fully enforceable date of February 2, 2026. The episode addresses industry complacency and details critical steps manufacturers must take immediately.

The episode debunks the myth that familiar quality documents like the DHF, DMR, and DHR are being eliminated. While the specific terms are removed from the regulation's language, their substance is retained and mapped to new, ISO-aligned conceptual requirements: the Device Master Record (DMR) becomes the Medical Device File (MDF), the Design History File (DHF) becomes the Design and Development File (DDP), and the Device History Record (DHR) is captured in the Batch or Lot Record. The host emphasizes that internal documents can retain the old terminology, provided a clear regulatory mapping is established.

Crucially, compliance requires more than just an ISO 13485 certificate. Two major philosophical shifts must be addressed: the explicit requirement for integrating lifecycle risk management as the DNA of the entire QMS, and the loss of the audit privilege, which makes internal audit reports, supplier audit reports, and management review records inspectable regulatory evidence. Furthermore, manufacturers must comply with retained, US-specific requirements under the QMSR's prevalence rule, especially concerning mandatory record content (§ 820.35) and specific labeling and packaging controls (§ 820.45).

Key Timestamps

1. [0:50] QMSR: The biggest shakeup to US quality requirements since 1996.
2. [2:00] Effective Date: February 2, 2026—the clock is ticking.
3. [2:42] The Goal: Harmonization with ISO 13485:2016 to reduce redundancy for global manufacturers.
4. [3:50] Myth 1 Busted: The FDA is eliminating the DHF, DMR, and DHR (Documentation Dissolution).
5. [5:10] Terminology Shift: DMR > Medical Device File (MDF, ISO 13485 Clause 4.2.3).
6. [6:30] Terminology Shift: DHF > Design and Development File (DDP, ISO 13485 Clause 7.3.10).
7. [7:40] Terminology Shift: DHR > Batch or Lot Record (ISO 13485 Clause 7.5.1).
8. [8:40] The Practical Takeaway: Internal naming is fine, but regulatory mapping is mandatory.
9. [10:30] Critical Shift 1: Risk Management is the DNA of the QMS—Explicitly required across all clauses.
10. [13:00] Critical Shift 2: Loss of the Audit Privilege—Internal audit and management review records are now inspectable.
11. [17:00] Critical Shift 3: Retained FDA Specifications (Prevalence Rule).
12. [17:35] Retained Req. A: Mandatory Record Keeping Content (21 CFR Part 820.35)—UDI/UPC in complaint/service records.
13. [19:00] Retained Req. B: Extended Record Retention Period (Device life, no less than two years).
14. [20:10] Retained Req. C: Specific Labeling and Packaging Controls (21 CFR Part 820.45)—Inspection for accuracy.
15. [22:00] Immediate Action Plan: Gap analysis and restructuring to the new terminology.

Quotes

"Your internal audit reports, your management review minutes, if you were expecting to keep those shielded from any outside eyes, they are now inspectable regulatory evidence." - Etienne Nichols

Takeaways

1. Mandatory Regulatory Mapping: Manufacturers must conduct a thorough mapping exercise to ensure their existing DMR, DHF, and DHR content fulfills the new requirements of the Medical Device File (MDF), Design and Development File (DDP), and Batch/Lot Records, respectively.
2. Embed Lifecycle Risk Management: The QMSR requires a holistic, lifecycle approach to risk management, making it an explicit core component of all QMS clauses (e.g., supplier controls, design and development), moving beyond isolated, perfunctory steps.
3. Prepare for Full Documentation Exposure (Regulatory): Recognize that the former privilege is gone; internal audit reports, supplier audit reports, and management review records are now subject to routine FDA inspection. Draft these documents with the utmost rigor and awareness of their new status as regulatory evidence.
4. Confirm Compliance with FDA Retained Sections: ISO 13485 certification is not enough. You must address the US-specific requirements retained under the prevalence rule, particularly the mandatory inclusion of UDI/UPC in complaint records (§ 820.35) and the strict labeling/packaging inspection controls (§ 820.45).
5. Transition is Immediate: The compliance date of February 2, 2026, is a hard deadline. Proactive gap analysis, process restructuring, and staff training based on the QMSR's requirements and the FDA's preamble are essential for uninterrupted market access.

References

1. ISO 13485:2016: The international Quality Management System standard for medical devices incorporated by reference into the QMSR.
2. 21 CFR Part 820 (New QMSR): The revised Code of Federal Regulations that replaces the QSR, incorporating ISO 13485 and retaining US-specific supplemental provisions.
3. 21 CFR Part 820.35 (Control of Records): Retained section requiring specific content, like UDI/UPC, for complaint and service records.
4. 21 CFR Part 820.45 (Device Labeling and Packaging Controls): Retained section requiring documented procedures for inspecting labeling and packaging accuracy.
5. QMSR Preamble: The FDA's detailed commentary and response to comments, which is crucial for understanding the Agency's interpretive thinking behind the new rule.
6. Etienne Nichols' LinkedIn: https://www.linkedin.com/in/etienne-nichols/

MedTech 101 Section

What is the "Prevalence Rule"?

The Prevalence Rule is a key concept in the new Quality Management System Regulation (QMSR) that clarifies which set of rules takes priority. Since the FDA is incorporating the international standard ISO 13485:2016 by reference, a conflict could arise between the ISO standard and existing U.S. law. The Prevalence Rule dictates that in any area of conflict, the U.S. Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations (like those retained in 21 CFR Part 820) will always supersede the ISO 13485 requirement. Think of it like a recipe: ISO 13485 is the main set of instructions, but the retained 21 CFR sections are non-negotiable, mandatory additions or modifications that must be followed regardless of what the main instructions say. This is why mere ISO certification does not guarantee QMSR compliance.

Sponsors

This episode is brought to you by Greenlight Guru. As the medical device industry faces the significant shift to the QMSR, your QMS needs to be audit-ready and easy to update. Greenlight Guru offers an all-in-one MedTech lifecycle excellence platform with specialized QMS and EDC solutions. Our electronic Quality Management System (eQMS) is built to facilitate the traceability and document control necessary to manage the new ISO-aligned terminology and retained FDA requirements, while our Electronic Data Capture (EDC) software helps manage high-quality data for clinical trials. Don't let scattered documentation hold you back from the February 2026 deadline. Visit www.greenlight.guru to learn how we can help you streamline your quality system and get back to innovating.

Feedback Call-to-Action

Did this episode help clarify your QMSR transition plan? We value your input and are dedicated to providing the most relevant, actionable content for MedTech professionals. Please send your feedback, questions, or topic suggestions directly to the host at podcast@greenlight.guru. We read every message and offer personalized responses, ensuring the Global Medical Device Podcast continues to serve your regulatory and quality needs. Also, take a moment to rate, review, and subscribe on your favorite podcast platform.

To thrive in this new environment, MedTech professionals, particularly those in Quality Assurance (QA) and Regulatory Affairs (RA), must expand their focus beyond technical competence. Elena stresses the growing importance of transverse skills (the essential human skills like communication, negotiation, and leadership) and, critically, AI literacy. With the pressure on companies to "do more with less," AI is creating an environment where smaller, highly productive teams are favored. This doesn't mean roles will disappear, but professionals must embrace technology to eliminate tedious tasks and focus on high-value, strategic work.

Navigating the job market now requires a more intentional and proactive approach, especially to access the hidden job market where the best unadvertised roles reside. Tactics include direct networking with hiring managers and active professional branding. Furthermore, the global regulatory environment's fragmentation—especially between the US (FDA) and EU (MDR/IVDR)—is impacting how companies build their teams, favoring remote work and strategic location choices that factor in the local talent pool and employment laws.

Key Timestamps

• 1:50 - The MedTech Talent Shift: From "War for Talent" to a "Reset"
• 4:45 - The impact of high volume and "easy apply" on candidate experience
• 6:15 - Immediate disqualification criteria and "gaming" the application system
• 7:35 - Strategies for accessing the hidden job market (networking and strategy)
• 9:20 - The controversial impact of AI on QA/RA roles and the need for efficiency
• 11:30 - Future-proofing your career: Why leaders and junior professionals must embrace AI
• 13:55 - Understanding transverse skills (soft skills) and business acumen
• 15:40 - The QA/RA role in the age of AI: Focusing on the 30% of high-value expertise
• 17:00 - Tactics for achieving AI literacy: Small wins, experimentation, and habit stacking
• 19:45 - Why the "hidden job market" exists (confidentiality, exclusivity, and pipeline)
• 21:30 - Positioning yourself externally: The power of active contribution on LinkedIn
• 23:45 - The importance of speaking at industry events (e.g., RAPS) to build credibility
• 24:55 - Strategic advice for founders building remote, global teams
• 26:15 - The impact of US vs. EU regulatory fragmentation on talent selection

Quotes

“It's not going to be enough to just be good at your job. You're going to need to have a little bit more understanding of how to position yourself, how to brand yourself, how building skills outside of just your technical competency [is important].” - Elena Kyria

“This is a massive opportunity... to step up and get started... you can use the technology but then you're focused on strategy, relationships, [and] the human side of it versus the people that are still very manual.” - Elena Kyria

Takeaways

• Prioritize AI Literacy: MedTech professionals must proactively experiment with AI tools (like note-takers and regulatory intelligence systems) to automate up to 70% of tedious tasks. Waiting for formal company training risks falling behind competitors who are already seeing a compounding effect from daily micro-improvements.
• Master Transverse Skills: Beyond technical QA/RA knowledge, focus on building "hard soft skills" like negotiation, communication, leadership, and financial/business acumen. These are the differentiating skills that AI cannot replicate and will define the strategic value of the future professional.
• Shift from Lurker to Contributor: Use LinkedIn strategically. Instead of passively scrolling, actively engage by adding meaningful, subject-matter expert comments to relevant posts. This builds credibility and positions you as a known contributor, enhancing your professional brand.
• Tap into the Hidden Job Market: Rely less on mass applications and more on strategic networking, building long-term relationships, and direct outreach to hiring managers. The best, often confidential, roles are frequently filled through these non-advertised channels.
• Global Teams Require Legal Due Diligence: Founders building remote teams must be acutely aware of local employment laws and benefits (e.g., maternity leave differences) in each geography. Talent decisions shouldn't just be based on cost or tax benefits but must factor in the available skill density in that location.

References

• Elemed: Elena Kyria's consultancy focused on MedTech executive hiring and recruitment strategy.
• RAPS (Regulatory Affairs Professional Society): Mentioned as a key platform for professional development and speaking opportunities within the MedTech regulatory field.
• Greenlight Guru QMS & EDC Solutions: Greenlight Guru's Quality Management System (QMS) helps MedTech companies simplify compliance, while their Electronic Data Capture (EDC) platform streamlines clinical trial data management.
• Etienne Nichols' LinkedIn: linkedin.com/in/etiennenichols

MedTech 101 Section

Transverse Skills vs. Technical Skills

In the MedTech industry, we often talk about technical skills—the specific knowledge needed for a job, such as knowing the difference between the FDA's 510(k) and the EU's MDR requirements.

Transverse Skills (historically called "soft skills") are the human abilities that apply across all roles and industries, and they are becoming the most critical skills for MedTech professionals in the age of AI.

Simple Analogy: Think of a medical device engineer:

• Technical Skill: Being able to design a circuit board or write a V&V protocol.
• Transverse Skill: Being able to clearly communicate the risks of that circuit board design to the management team, or negotiate with a supplier on quality specifications.

As AI takes over tasks like drafting initial documents or summarizing regulations, the uniquely human skills—like critical thinking, ethical judgment, leadership, and strategic communication—are what add true, irreplaceable value to a MedTech company.

Feedback Call-to-Action

Did this episode shift your perspective on AI or the job market? Your feedback helps us shape future content. We are committed to providing personalized and actionable advice to MedTech professionals globally. Please send your thoughts, reviews, or suggestions for future topics directly to podcast@greenlight.guru.

Sponsors

This episode of the Global Medical Device Podcast is brought to you by Greenlight Guru. In a market where MedTech talent must be highly productive and efficient, your tools should support that goal. Greenlight Guru offers solutions that help your teams do more with less: our industry-specific QMS streamlines your compliance and quality processes, while our EDC solution digitizes and simplifies your clinical data capture. Visit greenlight.guru to learn how you can upgrade your system to match your highly skilled workforce.

A significant focus is placed on the Software of Unknown Provenance (SOUP), treating these building blocks as purchased components that require robust supplier evaluation and validation, bridging Clause 7.5 (production) with Clause 7.4 (purchasing). The discussion extends to crucial concepts like the Software Bill of Materials (SBoM), the complexity of Agile vs. Waterfall approaches within the standard's framework, and the essential role of the new FDA Computer Software Assurance (CSA) guidance in risk assessment.

Beyond production, the experts explore the application of resource management (Clause 6), specifically addressing infrastructure, contamination control (malware/ransomware), and the critical need for a well-documented Design Transfer to Production (Clause 7.3.8) evidenced by a complete software release package, including all 62304 requirements. The episode provides actionable insights for quality and compliance professionals struggling to maintain speed and innovation while strictly adhering to regulatory requirements.

Key Timestamps

• 01:45 - The changing landscape: Why traditional MedTech rules struggle with modern software updates.
• 03:50 - Historical context of ISO 13485 and its non-distinction between hardware/software.
• 05:05 - Starting Point: Clause 7.5 (Production and Service Provision) and the "Virtual Manufacturing Space" concept.
• 06:20 - Unpacking Software of Unknown Provenance (SOUP) and its link to Clause 7.4 (Purchasing).
• 08:35 - The necessity of validating the development environment (GitHub/GitLab) and building blocks.
• 11:10 - Applying Clause 4.1.6 (Software Validation) to SOUP items and master validation plans.
• 12:20 - Applicable vs. Non-Applicable Clauses: Sterilization/Cleanliness vs. Installation.
• 13:55 - Clause 4.2.3 (Medical Device File) for SaMD: E-labels, UDI, System Architecture, and SBoM.
• 16:30 - Cybersecurity controls and the manufacturer's responsibility for identifying state-of-the-art standards.
• 17:35 - Defining "Production" for continuously updating software and managing significant vs. non-significant changes.
• 20:15 - Clash of Standards: Agile development, ISO 13485, and the missing documentation for version control risk assessment.
• 21:30 - Clause 6.3 & 6.4 (Resource & Work Environment): Looking at data security, access controls, and contamination (malware/ransomware).
• 24:45 - Clause 7.3.8 (Design Transfer to Production): The need for a formal software release package and the importance of the Software Design Trace Matrix.
• 26:00 - The 16 essential documents needed to meet IEC 62304 requirements.
• 27:10 - Production controls when the user influences the outcome (customizable features, disclaimers).

Quotes

"So my starting point really in this conversation is to cherry pick some of those clauses from ISO 13485, which are more akin to production. And then how do we then unpack that and apply it with medical device software in mind?" — Adnan Ashfaq

"You've got to look at data corruption, you've got to look at unauthorized code, you've got to look at version controlling malware or ransomware, you've got to look at that as well. That's all part of [contamination control, Clause 6.4.2]." — Adnan Ashfaq

Takeaways

• Adopt a "Virtual Manufacturing Space" Mindset: Treat your development environment (e.g., source control systems like GitHub/GitLab, compilers, cloud platforms) as a production floor that requires the same level of validation and control as a physical cleanroom or factory floor, satisfying ISO 13485 Clause 7.5.
• Validate SOUP as Purchased Products: Any Software of Unknown Provenance (SOUP) or open-source components must be treated as "purchased product" under Clause 7.4, requiring documented supplier verification, impact assessment, and validation (or documented rationale for non-validation) before integration into your SaMD.
• Contamination Control is Cybersecurity: ISO 13485 Clause 6.4.2, Contamination Control, must be applied to the digital sphere. This includes safeguards against malware, ransomware, unauthorized code, and data corruption, emphasizing the non-negotiable need for robust cybersecurity controls in your Quality Management System (QMS).
• Formalize the Software Bill of Materials (SBoM): The SBoM, detailing all software components, libraries, dependencies, and their version controls, is a key deliverable under Clause 4.2.3 (Medical Device File), acting as the digital equivalent of a Bill of Materials for Design Transfer to Production (Clause 7.3.8).
• Bridge Agile with Documentation: When using Agile development, ensure every iteration, bug fix, or patch includes a documented risk assessment (connecting to ISO 14971) and change history to satisfy ISO 13485’s traceability and control requirements, preventing potential non-conformances in audit.

References

• Etienne Nichols' LinkedIn: linkedin.com/in/etiennenichols
• ISO 13485:2016 (specifically Clauses 7.5, 7.4, 4.2.3, 6.3, 6.4, 7.3.8)
• IEC 62304 (Medical device software – Software life cycle processes)
• FDA Computer Software Assurance (CSA) Guidance: The new guidance replacing older process validation guidance, focusing on a risk-based approach (High Risk vs. Low Risk) for validating software tools.
• AAMI TIR 45 (Guidance on the use of agile practices in the development of medical device software)

MedTech 101 Section

Software of Unknown Provenance (SOUP)

SOUP refers to software components that have been developed for purposes other than being part of the medical device, and for which the developer did not use a medical device quality management system (QMS) process. In simple terms, it's off-the-shelf software (like an open-source library, a commercial operating system, or a third-party module) that you integrate into your SaMD.

Analogy: If you are building a custom, high-end car (your medical device), the engine block (the SaMD code) is custom-made. However, you decide to use commercially available tires, a standard battery, and a third-party GPS system (the SOUP items). While convenient, you can't be 100% sure how those other developers built them. To use them in your regulated medical product, you must perform your own testing and validation (verification) on the SOUP components to ensure they work reliably and safely within your device's specific intended use, treating them as if you purchased them from an outside supplier under Clause 7.4.

Feedback Call-to-Action

We thrive on your expertise and insights. If you have questions about applying ISO 13485 to your specific SaMD project, or if you'd like to suggest a topic for a future deep-dive, please send us an email. We read every message and offer personalized responses to help you navigate the complexities of MedTech compliance.

Contact us at: podcast@greenlight.guru

Sponsors

This episode discussing the critical balance of innovation and compliance in SaMD is brought to you by Greenlight Guru. In a world where software updates are weekly, using antiquated paper-based or general-purpose QMS systems is a compliance risk. Greenlight Guru offers MedTech-specific solutions, including a leading QMS platform and an advanced EDC solution, that are designed to handle the complexity of modern device development, like seamless traceability for your Software Bill of Materials and automated audit trails, ensuring you stay compliant with standards like ISO 13485 and IEC 62304.

Key Timestamps:

• [00:00:30] Introduction to Kavetha Ram and the episode's focus
• [00:05:15] Discussion on the challenges and opportunities of new regulations
• [00:10:40] Insights into the importance of confidence and adaptability in the regulatory field
• [00:15:20] Kavetha's journey and advice for emerging professionals
• [00:25:00] The role of innovation and collaboration in MedTech advancements
• [00:35:10] Strategies for professionals to stay relevant and proactive

Quotes:

• "Regulations are not just hurdles; they are stepping stones to innovation and safety in MedTech." - Kavetha Ram
• "Embracing change in regulations is not an option but a necessity for MedTech's future." - Etienne Nichols
• "Diversity in teams isn't just about varied backgrounds; it's about unlocking unique perspectives that drive innovation." - Kavetha Ram

Key Takeaways:

Insights into MedTech Trends:

1. Regulatory changes are both a challenge and an opportunity for innovation.

Practical Tips for MedTech Enthusiasts:

1. Stay updated with regulatory changes and understand their implications.
2. Engage in continuous learning and skill development.
3. Foster collaboration across disciplines to enhance innovation.

References:

• Kavetha Ram's LinkedIn Profile
• Etienne Nichols' LinkedIn Profile
• Greenlight Guru

Questions for the Audience:

• "What advice do you have for budding Regulatory Affairs professionals?"

Reach out to us and let us know what you thought of the episode at podcast@greenlight.guru

Also, if you enjoyed this episode, please leave us a review on iTunes!

Sponsors:

This episode is brought to you by Greenlight Guru, the only quality management software designed specifically for the medical device industry. Greenlight Guru's platform streamlines product development and compliance, making the process more efficient and less risky. Discover how Greenlight Guru can accelerate your product development at www.greenlight.guru.

Key Timestamps:

• 00:00:15 - Introduction of Perry Parendo and the episode's focus
• 00:03:50 - Discussing the challenges of MedTech product development and regulatory hurdles
• 00:12:20 - Agile methodologies vs. traditional project management in MedTech
• 00:22:35 - The importance of risk management and Monte Carlo simulation in project planning
• 00:34:10 - Perry's perspective on innovation, compliance, and balancing project priorities
• 00:45:55 - Strategies for efficient and effective product development processes

Quotes:

• "We're so focused from a compliance point of view on patient and health risk, we're not focused on project risk. And when I worked in the defense industry, we were hugely focused on project risk," Perry Parendo
• "There's waterfall, there's agile, there's Toyota, there's set based design, and there's APQP in the automotive industry. They're all a blend. There's no organization that's doing purely the theoretical of any one of those processes," Perry Parendo

Takeaways

Insights on MedTech Trends:

1. The convergence of agile and traditional methodologies tailored to MedTech's unique demands.
2. The rising importance of advanced risk management techniques, like Monte Carlo simulations, in navigating project uncertainties.
3. A call for innovation that transcends regulatory compliance to genuinely benefit patient care.

Practical Tips for Listeners:

1. Adopt a flexible approach to project management by integrating various methodologies based on project needs.
2. Prioritize risk management early in the development process to foresee and mitigate potential challenges.
3. Always align product development objectives with the ultimate goal of improving patient outcomes.

Questions for Future Developments:

1. How will evolving regulatory standards shape the next generation of medical devices?
2. What role will patient feedback play in the design and development of future MedTech innovations?
3. Can MedTech sustain its pace of innovation while ensuring safety and compliance?

References:

• Perry Parendo on LinkedIn
• Etienne Nichols on LinkedIn
• Behavioral Grooves podcast with Annie Duke - Thinking in Bets
• Book - Someday is Today, Ron Richard
• Youtube video - the Heartbeat of New Product Development
• Quality Culture for Product Design Success
• Design News Columns
• Practical Monte Carlo Analysis

Questions for the Audience:

• Poll: Which MedTech advancement do you believe will have the most significant impact on healthcare in the next decade?
• Discussion: How do you envision the future of healthcare changing with the continuous integration of MedTech innovations?

We're eager to hear your thoughts on this episode and your suggestions for future topics. Please share your feedback and leave us a review on iTunes!

For in-depth discussions and questions, email us at podcast@greenlight.guru

Sponsors:

This episode is brought to you by Greenlight Guru, the only quality management system (QMS) and electronic data capture (EDC) software designed specifically for the medical device industry. Make your product development process smoother, faster, and compliant with Greenlight Guru. Discover the difference at www.greenlight.guru

Quotes

1. "If you're not talking about the value that you add, how is anybody going to know what impact you're having?" - Elena Kyria
2. "Everything's uncertain really, isn't it? What you've got to have is a clear sense of forwards and just have a goal." - Elena Kyria
3. "Nobody goes to the gym and looks at the weights and gets fit. You have to do the reps." - Elena Kyria

Takeaways

1. Networking is Key: It's not just what you know, but who knows you and what they know you're doing.
2. Visibility of Achievements: Share your successes within your company; if you don't, others may not recognize your contributions.
3. Defining Success: Success doesn't always mean reaching the VP level; it's about personal satisfaction and contribution.
4. Strengths and Weaknesses: Focus on your strengths but be aware of your weaknesses and compensate with your team.
5. Career Paths: Understand the different career paths (leadership, expert, generalist) and what they entail for growth.
6. Communication Skills: Strong communication skills are paramount for leadership and for translating technical details to a broader audience.
7. Continuous Learning: Always seek new knowledge and experiences, no matter where you are in your career.
8. Adaptability: Be prepared to pivot and adapt to changes within the industry and your career.
9. Take Action: Don't just reflect on advice; apply it to make actual changes in your career approach.

Reference Links:

• Elena Kyria's LinkedIn
• Elemed
• Working Genius
• Greenlight Guru
• Etienne Nichols' LinkedIn

Remember to engage with the hosts and guests on LinkedIn for feedback and further discussions.

Don’t forget to leave a review on iTunes!

*Interested in sponsoring an episode? Use this form and let us know!

The conversation addresses how global medical device companies can structure their strategy amid ongoing geopolitical shifts and the "China for China" policy, which favors domestic products through initiatives like the Volume-Based Procurement (VBP). Strategies such as the dual-strategy approach—localizing low-consumable manufacturing while protecting high-technology IP through joint ventures or careful CMO/CDMO selection—are explored as pragmatic ways to secure market presence and margin. Understanding the regulatory landscape, particularly the NMPA's 2021 overhaul, is crucial for success.

Finally, Elaine provides practical guidance for regulatory professionals intimidated by the market. This includes understanding the specific regulatory and clinical pathways, performing a gap analysis against Chinese standards (Product Technical Requirements or PTR), and the critical process of selecting and qualifying a local partner/agent. Elaine reveals a specific, often overlooked hurdle: the agent must possess an NMPA-approved CA (Certification Authorization) USB key to electronically submit registration files on behalf of the foreign manufacturer, a critical piece of the submission puzzle. The discussion also touches on leveraging special zones, like the Hainan Free Trade Zone, for crucial real-world data collection applicable to the Chinese population.

Key Timestamps

• [02:40] Introduction to Elaine Tan, MedTech Chopsticks, and the show’s focus on the China market.
• [05:05] High-level risks and rewards: complexity, lengthy registration, local testing requirements, and IP concerns.
• [08:08] Discussing the NMPA's 2021 regulatory overhaul and the geopolitical shift toward "China for China."
• [11:00] The Dual Strategy approach: balancing low-end localization with protecting high-tech IP.
• [14:48] Using CDMOs/CMOs for pilot projects to manage financial investment risk.
• [16:20] Leveraging the Hainan Free Trade Zone (Bo’ao region) for pre-market clinical data collection and urgent needs product access.
• [18:42] Ethological differences and their impact on clinical data justification (e.g., Pulse Oximeters).
• [20:17] NMPA predicate search: The importance of using the Chinese Classification Catalog to find registered, local predicate devices.
• [23:00] Guidance for overwhelmed regulatory professionals entering the China market: Clinical strategy and Product Technical Requirements (PTR).
• [25:52] Pitfalls in partner selection: The necessity of the NMPA-approved CA (Certification Authorization) USB key for submissions.
• [29:30] Partner qualification: Ensuring the agent can support Post-Market Surveillance (PMS) and QMS self-inspection requirements.
• [30:52] Final pitfall: International compliance (ISO/IEC) does not automatically ensure China compliance.

Quotes

"The requirements that you have fulfilled in the earlier stages might not be sufficient to enter market. They need to have local testing [and] need to compliant with the local standard." - Elaine Tan

"For China, NMPA would like to actually emphasize that you need to select a predicate which has been approved in China markets already... This product have to be already registered to be valid and to be applicable to be used as a predicate device." - Elaine Tan

Takeaways

1. Mandatory Localization is Key: Be aware that high international compliance (ISO, IEC) does not substitute for mandatory local type testing and adherence to China's specific Product Technical Requirements (PTR). Factor this into your R&D and budget early on.
2. Employ a Dual-Strategy for IP: For high-tech, innovative products, avoid placing core IP entirely within China. Consider a hybrid structure using joint ventures, strategic CMO/CDMO partnerships, or utilizing international patents to safeguard your know-how while localizing the manufacturing of less innovative consumables.
3. Leverage Special Pathways: Explore regional initiatives like the Hainan Free Trade Zone (Bo’ao region). This area allows for early, pre-market clinical collaborations to collect essential real-world data on the Chinese population, which is often required to justify clinical significance based on ethological differences (differences based on race/demographic).
4. Vet Your China Agent Rigorously: The most critical qualification for your foreign regulatory agent is not just experience, but their possession of the NMPA-issued CA (Certification Authorization) USB key. Without this physical credential, they cannot electronically submit your registration files.
5. Understand NMPA Predicate Rules: When developing your clinical strategy, the NMPA requires the selection of a predicate device that is already approved and registered in the Chinese market, regardless of whether it is domestic or foreign-made. Use the NMPA Classification Catalog to find the correct "common name" to search their database effectively.

References:

• NMPA (National Medical Products Administration): The regulatory authority in China responsible for medical device approvals and oversight.
• Product Technical Requirements (PTR): A key NMPA requirement document defining the specific performance, testing, and compliance standards for a medical device in China.
• Hainan Free Trade Zone (Bo'ao region): A special economic and medical tourism zone that permits the use of certain internationally approved, urgently needed medical devices before formal NMPA registration, allowing for local clinical data collection.
• Elaine Tan's LinkedIn
• Etienne Nichols' LinkedIn: Connect with Etienne

MedTech 101 Section

Ethological Differences: In the context of medical devices and clinical trials, "ethological differences" refers to the variations in biological, anatomical, or physiological characteristics between different human races or demographic populations. A classic example is a pulse oximeter: because the device measures oxygen saturation based on light absorption in the blood, the different skin tones across populations can affect the light's absorption rate. Therefore, data collected only on one demographic may be insufficient to prove clinical safety and efficacy in another, requiring local testing for products sensitive to these population differences.

CA (Certification Authorization) USB Key: This is a crucial physical piece of hardware, similar to a security token, issued by the NMPA to accredited foreign manufacturer agents. It functions as a unique digital signature and login credential, which must be plugged into a computer for the agent to access the NMPA's electronic platform and successfully submit all regulatory and registration documents. Its possession is non-negotiable for an agent handling foreign medical device registrations.

Feedback Call-to-Action

We want to hear from you! Your feedback is invaluable in shaping the future of the Global Medical Device Podcast. Did this discussion help clarify your strategy for the Chinese market? Do you have experience with the NMPA's CA key or the Hainan Free Trade Zone? Send your comments, feedback, or suggestions for future topics directly to podcast@greenlight.guru. We emphasize personalized responses, so reach out—we’d love to hear your insights.

Sponsors

This episode is brought to you by Greenlight Guru, the only MedTech-specific platform providing both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions. Navigating the regulatory complexities of the Chinese market, including meeting the rigorous Product Technical Requirements (PTR) and managing extensive documentation, demands a specialized system. Greenlight Guru's platform is designed to streamline compliance for multiple global markets, ensuring you have a secure and compliant foundation for your device’s entire lifecycle, whether you're dealing with local type testing or]]>This episode dives into the complex and often misunderstood MedTech market in China, featuring Elaine Tan, creator of MedTech Chopsticks, who translates the nation’s stringent regulatory language into actionable insights. Elaine and host Etienne Nichols discuss the substantial risks and rewards of bringing a medical device to China, highlighting the country's rapid execution, intense internal competition, and the shift from low-end manufacturing to a focus on high-level innovation. A key risk is that existing international certifications (like ISO and IEC) do not guarantee compliance, requiring local type testing and adherence to specific national standards.

The conversation addresses how global medical device companies can structure their strategy amid ongoing geopolitical shifts and the "China for China" policy, which favors domestic products through initiatives like the Volume-Based Procurement (VBP). Strategies such as the dual-strategy approach—localizing low-consumable manufacturing while protecting high-technology IP through joint ventures or careful CMO/CDMO selection—are explored as pragmatic ways to secure market presence and margin. Understanding the regulatory landscape, particularly the NMPA's 2021 overhaul, is crucial for success.

Finally, Elaine provides practical guidance for regulatory professionals intimidated by the market. This includes understanding the specific regulatory and clinical pathways, performing a gap analysis against Chinese standards (Product Technical Requirements or PTR), and the critical process of selecting and qualifying a local partner/agent. Elaine reveals a specific, often overlooked hurdle: the agent must possess an NMPA-approved CA (Certification Authorization) USB key to electronically submit registration files on behalf of the foreign manufacturer, a critical piece of the submission puzzle. The discussion also touches on leveraging special zones, like the Hainan Free Trade Zone, for crucial real-world data collection applicable to the Chinese population.

Key Timestamps

• [02:40] Introduction to Elaine Tan, MedTech Chopsticks, and the show’s focus on the China market.
• [05:05] High-level risks and rewards: complexity, lengthy registration, local testing requirements, and IP concerns.
• [08:08] Discussing the NMPA's 2021 regulatory overhaul and the geopolitical shift toward "China for China."
• [11:00] The Dual Strategy approach: balancing low-end localization with protecting high-tech IP.
• [14:48] Using CDMOs/CMOs for pilot projects to manage financial investment risk.
• [16:20] Leveraging the Hainan Free Trade Zone (Bo’ao region) for pre-market clinical data collection and urgent needs product access.
• [18:42] Ethological differences and their impact on clinical data justification (e.g., Pulse Oximeters).
• [20:17] NMPA predicate search: The importance of using the Chinese Classification Catalog to find registered, local predicate devices.
• [23:00] Guidance for overwhelmed regulatory professionals entering the China market: Clinical strategy and Product Technical Requirements (PTR).
• [25:52] Pitfalls in partner selection: The necessity of the NMPA-approved CA (Certification Authorization) USB key for submissions.
• [29:30] Partner qualification: Ensuring the agent can support Post-Market Surveillance (PMS) and QMS self-inspection requirements.
• [30:52] Final pitfall: International compliance (ISO/IEC) does not automatically ensure China compliance.

Quotes

"The requirements that you have fulfilled in the earlier stages might not be sufficient to enter market. They need to have local testing [and] need to compliant with the local standard." - Elaine Tan

"For China, NMPA would like to actually emphasize that you need to select a predicate which has been approved in China markets already... This product have to be already registered to be valid and to be applicable to be used as a predicate device." - Elaine Tan

Takeaways

1. Mandatory Localization is Key: Be aware that high international compliance (ISO, IEC) does not substitute for mandatory local type testing and adherence to China's specific Product Technical Requirements (PTR). Factor this into your R&D and budget early on.
2. Employ a Dual-Strategy for IP: For high-tech, innovative products, avoid placing core IP entirely within China. Consider a hybrid structure using joint ventures, strategic CMO/CDMO partnerships, or utilizing international patents to safeguard your know-how while localizing the manufacturing of less innovative consumables.
3. Leverage Special Pathways: Explore regional initiatives like the Hainan Free Trade Zone (Bo’ao region). This area allows for early, pre-market clinical collaborations to collect essential real-world data on the Chinese population, which is often required to justify clinical significance based on ethological differences (differences based on race/demographic).
4. Vet Your China Agent Rigorously: The most critical qualification for your foreign regulatory agent is not just experience, but their possession of the NMPA-issued CA (Certification Authorization) USB key. Without this physical credential, they cannot electronically submit your registration files.
5. Understand NMPA Predicate Rules: When developing your clinical strategy, the NMPA requires the selection of a predicate device that is already approved and registered in the Chinese market, regardless of whether it is domestic or foreign-made. Use the NMPA Classification Catalog to find the correct "common name" to search their database effectively.

References:

• NMPA (National Medical Products Administration): The regulatory authority in China responsible for medical device approvals and oversight.
• Product Technical Requirements (PTR): A key NMPA requirement document defining the specific performance, testing, and compliance standards for a medical device in China.
• Hainan Free Trade Zone (Bo'ao region): A special economic and medical tourism zone that permits the use of certain internationally approved, urgently needed medical devices before formal NMPA registration, allowing for local clinical data collection.
• Elaine Tan's LinkedIn
• Etienne Nichols' LinkedIn: Connect with Etienne

MedTech 101 Section

Ethological Differences: In the context of medical devices and clinical trials, "ethological differences" refers to the variations in biological, anatomical, or physiological characteristics between different human races or demographic populations. A classic example is a pulse oximeter: because the device measures oxygen saturation based on light absorption in the blood, the different skin tones across populations can affect the light's absorption rate. Therefore, data collected only on one demographic may be insufficient to prove clinical safety and efficacy in another, requiring local testing for products sensitive to these population differences.

CA (Certification Authorization) USB Key: This is a crucial physical piece of hardware, similar to a security token, issued by the NMPA to accredited foreign manufacturer agents. It functions as a unique digital signature and login credential, which must be plugged into a computer for the agent to access the NMPA's electronic platform and successfully submit all regulatory and registration documents. Its possession is non-negotiable for an agent handling foreign medical device registrations.

Feedback Call-to-Action

We want to hear from you! Your feedback is invaluable in shaping the future of the Global Medical Device Podcast. Did this discussion help clarify your strategy for the Chinese market? Do you have experience with the NMPA's CA key or the Hainan Free Trade Zone? Send your comments, feedback, or suggestions for future topics directly to podcast@greenlight.guru. We emphasize personalized responses, so reach out—we’d love to hear your insights.

Sponsors

This episode is brought to you by Greenlight Guru, the only MedTech-specific platform providing both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions. Navigating the regulatory complexities of the Chinese market, including meeting the rigorous Product Technical Requirements (PTR) and managing extensive documentation, demands a specialized system. Greenlight Guru's platform is designed to streamline compliance for multiple global markets, ensuring you have a secure and compliant foundation for your device’s entire lifecycle, whether you're dealing with local type testing or post-market surveillance audits.

Alex and host Etienne Nichols discuss the immense value of having a diverse internal team of consultants to draw from—a collective knowledge base that helps solve complex problems for clients. They emphasize that quality professionals don't need to know "everything" but rather must have the right resources and a "beginner's mindset" to guide companies effectively. The conversation also explores how modern software, like Greenlight Guru's QMS and EDC solutions, eliminates common industry pain points, such as fragmented, error-prone spreadsheet-based design controls by building true, linked traceability directly into the eQMS.

Finally, the discussion touches on the philosophical "why" of the medical device industry: the patient. Alex shares a personal story about how orthopedics improved his grandfather's quality of life, underscoring the importance of maintaining a patient-first ethos. They conclude by discussing the upcoming QMSR transition, reassuring listeners that compliance is manageable, especially for those already adhering to ISO 13485.

Key Timestamps

• [01:50] Alex Naber's MedTech Career Path: From Bioengineering to Design Quality and Post-Market Management.
• [04:30] The Power of Pooled Expertise: Why Greenlight Guru's Consultant Team is a "Sherpa up the mountain."
• [07:35] The Problem with Spreadsheets: Comparing traditional Design Control methods to modern eQMS traceability.
• [11:00] Accelerating Compliance: How Greenlight Guru's QMS Templates dramatically cut implementation time.
• [13:30] The Bloated QMS: Why adopting procedures from large corporations may hinder small-to-midsize companies.
• [16:00] Design Quality Explained: Marrying R&D/Product Development with QMS compliance.
• [21:30] The MedTech Ethos: Focusing on the patient and improving quality of life.
• [27:00] CAPA Management Insights: The critical distinction between Correction and Corrective Action.
• [30:25] Navigating the QMSR Transition: Reassurance that compliance isn't "that deep" if you are already ISO 13485 compliant.

Quotes

"It's a rewarding thing to just understand that you don't need to know everything. I think that's a thing that... people should realize and they should reach out to other people that are smarter or more experienced in realms that they don't understand." - Alex Naber

"I think what got me into MedTech was more of the ethos behind it... We're creating products to make patients' lives better, to impact our world, our society in a positive manner, to give a better quality of life to individuals." - Alex Naber

Takeaways

1. Seek a Unified Quality Solution: Fragmented quality processes (e.g., design controls in spreadsheets separate from the QMS) introduce significant regulatory risk. Adopting an eQMS, like the Greenlight Guru QMS solution, creates true traceability and dramatically streamlines compliance.
2. Design Quality as a Partner, Not Police: Design Quality Engineers should actively partner with R&D, not just enforce rules. This involves educating product development teams on the why behind documentation and regulations to collaboratively find compliant solutions.
3. Implement CAPA Early and Correctly: A robust CAPA process is essential long before market entry. Quality professionals must know the difference between a correction (fixing the immediate issue) and a corrective action (addressing the root cause) to prevent systemic non-conformances.
4. Leverage QMS Templates for Speed: For new or growing companies, utilizing pre-validated QMS templates, like those offered by Greenlight Guru, can cut months off the time required to establish a 13485 or FDA CFR Part 820/EU MDR compliant system.
5. QMSR is Not Overwhelming: As the QSR evolves into the Quality Management System Regulation (QMSR), companies already adhering to ISO 13485 will find the transition is relatively minor, primarily requiring minor updates rather than a complete overhaul of their existing QMS.

References

• Alex Naber's LinkedIn
• Etienne Nichols' LinkedIn: Connect with Etienne
• ISO 13485:2016: The international standard specifying requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. Relevance: This is the foundation for managing QMS changes, including the QMSR transition.
• Quality Management System Regulation (QMSR): The upcoming modernization of the FDA’s Quality System Regulation (21 CFR Part 820), harmonizing U.S. requirements with ISO 13485. Relevance: The central regulatory change discussed at the end of the episode.

MedTech 101 Section

Design Quality: In the medical device industry, Design Quality (DQ) is a specialized function within the Quality Assurance (QA) department. Its role is to ensure that the process used to design and develop a new medical device is compliant with the company's QMS procedures and applicable regulations (like FDA 21 CFR Part 820 or ISO 13485). Think of Design Quality as the engineer's compass and map for compliance—they guide the R&D team to make sure every requirement, test, and risk mitigation is properly documented and linked, preventing costly issues down the line. Without DQ, R&D teams might build a great product that can't be legally sold.

Correction vs. Corrective Action: These two terms are often confused in quality management:

• Correction: The immediate action taken to fix a non-conforming issue. Example: A batch of surgical instruments has burrs, so the correction is to re-polish them.
• Corrective Action (CAPA): A deeper, systemic action taken to eliminate the root cause of a non-conformance so it does not happen again. Example: The corrective action is revising the manufacturing work instruction to include mandatory daily calibration of the machine causing the burrs.

Feedback Call-to-Action

We want to be your trusted voice in MedTech! We are committed to providing the most useful, actionable insider knowledge in the industry. Please help us by sharing your thoughts on this episode, suggesting future topics, or leaving a personalized review on your favorite podcast platform.

Send your feedback, topic ideas, and questions directly to podcast@greenlight.guru. We personally read every email and truly value your input.

Sponsors

This episode of the Global Medical Device Podcast is brought to you by Greenlight Guru, the only MedTech-specific platform that provides both a powerful Quality Management System (QMS) and industry-leading Electronic Data Capture (EDC) solutions. Alex Naber, an expert consultant from Greenlight Guru, highlights in this episode how integrating your design controls—the subject of his design quality expertise—directly into a compliant eQMS is the key to accelerating product development, eliminating audit anxiety, and truly improving the quality of life for patients. To learn more about how Greenlight Guru's dedicated solutions can streamline your path to market, visit www.greenlight.guru.

The discussion delves into the historical context of the word "patient," which is rooted in the Latin patior, meaning 'to suffer.' Dr. Komiyama shares insights from industry conferences, noting that many individuals prefer to be called a "person" or an "empowered patient" rather than a passive sufferer. This ties directly into the growing movement of individuals seeking to own their health and be active participants in their care, fueled by readily available information and a focus on health span over just disease treatment.

Ultimately, the key takeaway for MedTech innovators is the importance of understanding their end-user and tailoring their language—in labeling, clinical studies, and human factors testing—to align with the user's preferred terminology. The shift from "caregiver" to "care partner" is highlighted as a prime example of evolving language that acknowledges a collaborative, mutual relationship, moving away from a hierarchical structure to one of shared purpose.

Key Timestamps

• [0:01:25] - Introduction to Dr. Allison Komiyama and Blue Stocking Health's mission to amplify the good of MedTech.
• [0:04:14] - Discussion begins: Patient vs. Customer vs. User in MedTech.
• [0:06:05] - The etymology of "patient" (patior, to suffer) and the push for "person" or "empowered patient."
• [0:08:22] - Historical context: Passivity of the patient role and the doctor's assumed knowledge.
• [0:09:50] - The impact of consumerism, AI, and the "health span" movement on patient empowerment.
• [0:12:35] - The value of seeking multiple opinions and the role of patient priorities in customizing care.
• [0:15:30] - Shifting terminology: Why "caregiver" is moving toward "care partner."
• [0:18:22] - How language diversity enriches the conversation and enhances communication.
• [0:21:00] - Tying diverse language use to MedTech innovation and product development.
• [0:22:15] - The importance of understanding end-user biases and assumptions in MedTech.
• [0:24:25] - Impactful personal stories: How specific interactions define a positive care experience.
• [0:29:10] - Concluding thoughts: Why plurality and qualifiers (e.g., "empowered patient") may be the ideal goal.

Quotes

"I think there's a lot of folks at FDA even that we're like, we don't want to use the word patient. We want to use the word person. And patient actually comes from the term patior, which means to suffer." - Dr. Allison Komiyama

Takeaways

1. Regulatory & Clinical Strategy: When defining the target population for your device—in 510k, IDE, or PMA submissions—be mindful of the terminology. Consider using terms like "end-user," "person living with [condition]," or "care partner" alongside "patient" to reflect a modern, inclusive understanding of the device's human context.
2. Human Factors & Usability: Language directly impacts product use. As an R&D or Human Factors professional, align your labeling and instructions with the language that resonates most with your defined user group. Utilizing terms like "care partner" for non-professional support ensures that instructions for use are mutually supportive and not hierarchical.
3. Marketing & Communication: MedTech companies should audit their external communications, including advertisements and white papers. A focus on "customer service" aspects (efficiency, speed, clear communication) can resonate more with the consumer/customer mindset than traditional "patient" messaging, provided it is balanced with clinical integrity.
4. Quality Management Systems (QMS) & Design Input: Use diverse language during design input collection to capture a broader range of needs. Focus groups that employ words like "user experience" and "customer journey" often uncover different, yet equally critical, insights compared to those solely focused on "patient safety" and "treatment protocol." Greenlight Guru's QMS and EDC solutions help capture and manage these diverse inputs effectively, ensuring alignment with both clinical and user needs.
5. Professional Dialogue: Embrace "strong opinions held loosely." MedTech leaders should cultivate internal and external dialogues that challenge existing assumptions about user terminology. A willingness to be corrected is key to identifying blind spots in product development and market strategy.

References

• Dr. Allison Komiyama's LinkedIn
• Etienne Nichols' LinkedIn: Connect with Etienne
• Blue Stocking Health: A company dedicated to redefining and amplifying the conversation around medical technologies.
• The Media Bias Chart / Ad Fontes Media (Vanessa Otero): Mentioned in the episode as an example of thoughtful dialogue and understanding different perspectives.

MedTech 101 Section

Caregiver vs. Care Partner

In the MedTech and healthcare world, the distinction between Caregiver and Care Partner is an important example of evolving language.

• Caregiver: Traditionally, this term suggests a one-way, hierarchical relationship where one person provides care and the other passively receives it. It often implies a professional role or a person solely responsible for the physical needs of another.
• Care Partner: This term signifies a mutual, collaborative relationship. It acknowledges that the person with the health condition is an active participant in their own care and that their support person (spouse, family member, friend) is working alongside them to manage the condition. It's a key linguistic shift that promotes empowerment and shared decision-making.

Analogy: Think of a dance. A Caregiver might be seen as the instructor directing every move, while a Care Partner is an equal on the dance floor, moving together with shared goals and rhythm.

Feedback Call-to-Action

We want to hear from you! Do you prefer to be called a patient, a customer, or a partner in your health journey? Your feedback drives our content and helps us bring the most relevant topics to the MedTech industry. Send your thoughts, episode reviews, and topic suggestions directly to us at podcast@greenlight.guru. We read every email and aim to offer personalized responses.

Sponsors

This episode of the Global Medical Device Podcast is brought to you by Greenlight Guru. In a complex and evolving industry, managing your processes efficiently is critical. Greenlight Guru provides the industry's leading suite of solutions: a Medical Device QMS to simplify compliance and accelerate product development, and Clinical Data Solutions (EDC) to streamline and digitize your clinical trials. The ability to embrace a user-centric approach, whether you call them a patient or a customer, requires robust quality and clinical data infrastructure—precisely what Greenlight Guru delivers. Learn how their solutions can power your next-generation medical device innovation.

The discussion pivots to the significant slowdowns that occur, notably the suspension of non-MDUFA-goal-tied interactions, such as Q-submissions (Pre-Submissions) and most interactive reviews. For startups and small manufacturers, the halting of the crucial small business designation processing can be particularly detrimental, leading to astronomically higher user fees once the government reopens. Michael emphasizes that the industry should anticipate this political risk and plan submission timelines strategically, positioning a government shutdown as an "uncontrollable natural disaster" that requires proactive risk mitigation.

Michael provides actionable advice for MedTech leaders to pivot during a shutdown. He recommends using the enforced delay to significantly improve the quality of submissions—making them easier to navigate and review once the FDA is fully operational—to gain a crucial advantage over the backlog of queued submissions. Furthermore, companies should utilize the time to focus on parallel activities such as process validation, refining quality systems, and strengthening commercial and reimbursement strategies. Michael stresses the importance of remembering the core mission: getting life-improving technologies to patients, and using any delay as an opportunity to emerge stronger and more prepared for commercial launch.

Key Timestamps

• 1:45 - The initial effects of a shutdown: What truly stops at the FDA (new submissions) versus what keeps running (existing reviews, IDEs, post-market surveillance).
• 3:50 - Why active review of filed submissions continues—the role of the user fee "reserve."
• 5:58 - Critical functions that stop or slow down: Pre-submissions (Q-subs), interactive reviews, new policy guidance, and routine inspections.
• 7:25 - The major impact of halting the small business designation process on user fees for new manufacturers.
• 8:36 - MDUFA (Medical Device User Fee Amendments) explained: How user fees fund the FDA and maintain operations during a lapse.
• 11:51 - Direct effects on a MedTech company's runway and the loss of interactive review.
• 13:17 - Actionable advice: Improving submission quality for easier review to mitigate the post-shutdown backlog.
• 15:00 - Strategic pivot: Focusing on parallel work like process validation and quality system refinement.
• 16:03 - Communicating with investors and partners: Positioning the shutdown as an uncontrollable event and shortening the commercial launch gap.
• 18:50 - Looking ahead: Planning submissions around budget resolution deadlines to anticipate shutdown risk.
• 20:53 - Final advice: Keeping the patient-focused mission in mind and maximizing internal efforts.

Quotes

"Active review of device submissions, if you already had something in or you were smart enough, you saw the writing on the wall, you got it in on September 30, you’re good to go. Those will still keep going on schedule with and the FDA is going to try to meet their MDUFA goals..." - Michael Nilo

"If yours stands out as being something that is easier to handle, makes it easier to process, they can navigate through it better, you have a better chance of getting a quicker, faster, better review process once it’s opened up."

Takeaways

1. Regulatory Strategy & Submission Quality: Use any government shutdown delay to drastically improve the navigability and clarity of your marketing submission (PMA, 510(k)). A well-organized, hyperlinked, and clear application will likely be processed faster by reviewers facing a post-shutdown submission backlog.
2. Financial Risk & Small Business Designation: Small medical device manufacturers should anticipate potential government shutdowns and file their small business designation application well in advance. Failure to process this designation during a lapse can result in paying the full, significantly higher user fee, which dramatically impacts startup runway.
3. Operations & Quality Focus: While regulatory submissions are stalled, pivot R&D and Quality teams to focus on parallel work streams. This includes advancing process validation, completing outstanding quality system activities (e.g., risk management file updates), and solidifying commercialization and reimbursement strategies.
4. IDE Reviews Continue: Companies initiating clinical trials should note that Investigational Device Exemption (IDE) submissions are generally considered essential and will still be reviewed within the MDUFA 30-day timeline. This is one of the few submission types that allows for continued progress during a shutdown.
5. Leverage User Fee Systems: Understand that the FDA's user fee structure (MDUFA) ensures that key pre- and post-market safety functions, as well as active review of existing applications, can be maintained for a period, acting as a crucial shock absorber for the industry.

References

• Michael Nilo's LinkedIn
• Etienne Nichols' LinkedIn: Connect with Etienne
• MDUFA (Medical Device User Fee Amendments): The legislation that authorizes the FDA to collect fees from companies that submit certain marketing applications for medical devices, which funds a significant portion of the agency's device-related activities and performance goals.
• IDE (Investigational Device Exemption): An FDA process that allows a device that is not yet legally marketed to be used in a clinical study to collect safety and effectiveness data. IDE reviews are generally protected during a shutdown.

MedTech 101 Section: User Fees and the MDUFA Buffer

When the U.S. government shuts down, it means Congress hasn't passed a budget, and non-essential federal agencies must pause most operations because their taxpayer funding stops. However, the FDA has a financial safety net for its medical device work: User Fees, authorized by the Medical Device User Fee Amendments (MDUFA).

Think of MDUFA as a dedicated savings account funded by MedTech companies. When a company submits a major application like a 510(k) or PMA, they pay a fee. This money goes into a separate reserve. When a government shutdown happens, the FDA can tap into this reserve to keep essential, MDUFA-related work going. This includes the salaries of reviewers who are already working on your application, ongoing post-market surveillance, and crucial safety functions. The money acts as a buffer, allowing the FDA to continue its core mission for a limited time, which is why existing reviews aren't immediately halted. New submissions, however, often can't be processed because that intake and processing function is deemed non-essential and is not typically covered by the emergency user fee funding.

Feedback Call-to-Action

We thrive on your input! If this discussion about government shutdowns and MedTech strategy sparked any thoughts, or if you have a topic you'd like us to cover, we want to hear from you. Email us directly at podcast@greenlight.guru. We personally read every email and are committed to providing you with the most relevant and actionable MedTech insights.

Sponsors

This episode is brought to you by Greenlight Guru, the only MedTech-specific platform providing end-to-end solutions. Don't let a government shutdown pause your internal quality momentum. Leverage Greenlight Guru's eQMS and EDC solutions to keep your product development, design controls, and clinical data management moving forward, ensuring your systems are inspection-ready and helping you build a submission so flawless it cuts through the FDA's post-shutdown backlog. Visit www.greenlight.guru to learn more.

Shannon explains the core principles of andragogy: adults are self-directed, problem-centered, and bring a vast reservoir of experience to the table (schema theory). They are less motivated by sequential, externally guided learning and more by what is relevant, timely, and what is in it for them. This self-directed approach means successful training in MedTech requires catering to intrinsic motivation and providing tactile, real-world practice rather than just videos or documentation.

The conversation pivots to practical applications across the medical device lifecycle. Shannon shares compelling examples, like improving physician adoption of a medical device by shifting the focus from extrinsic financial rewards and regulatory compliance to the intrinsic motivation of improving patient health outcomes. By making users part of the development process and using performance feedback to tap into a professional's competitive spirit, organizations can achieve significantly higher engagement and successful adoption of new technologies.

Key Timestamps

• [03:20] What is Andragogy? How adults learn differently than children.
• [04:45] The role of schema theory and existing experience in adult learning.
• [05:40] Why the traditional "drop 40 SOPs" on a new hire’s desk fails adults.
• [07:15] Case Study: The challenge of low medical device adoption and the missing education piece.
• [08:50] The power of tactile practice and addressing user confidence (e.g., misusing the device).
• [11:00] Contrasting Andragogy (self-directed) vs. Pedagogy (directed/sequential).
• [14:10] Applying adult learning to device development: solving the user's problem.
• [16:45] How to boost adoption: Intrinsic motivation and making users part of the process.
• [18:20] The key physician motivator: Desire to help people over money or administrative requirements.
• [21:10] Behavior science: Focusing on influential champions and mid/top performers for diffusion.
• [22:45] The "Gold Star" effect: Using competitive spirit and relevant KPIs for motivation.

Quotes

"The way we come to learning with adults is different... The best way that they learn is coming up with things that are relevant to them, things that are timely, things that they need. They want to be interested." - Shannon Decker

"I don't talk about the money that they're going to make... What I talk to them about is by paying attention and doing these screening exams, you're going to have an impact on the overall health of your patient." - Shannon Decker

Takeaways

1. Stop Relying on Documentation for Training: Adult learners need tactile input and practice. Replace or supplement large volumes of SOP reading with project team involvement, practical exercises, and hands-on use to build confidence and retention.
2. Focus on the "What's In It For Me" (WIIFM): When designing a medical device or a training program, identify the user’s intrinsic motivations. For clinicians, this is often the desire to improve patient outcomes—lead with this message rather than revenue or regulatory burden.
3. Build Champions, Not Just Compliance: Instead of solely focusing energy on low performers or the loudest voices, identify respected, influential leaders (champions) to pilot and advocate for new technology. Their positive experience drives the Law of Respect and encourages wider adoption.
4. Use Performance Data as a Motivator: Feedback and benchmarking can tap into a professional’s competitive spirit. Monitor device usage and provide timely, relevant feedback (the "Gold Star" effect) using KPIs that matter to their professional values, not just revenue goals.
5. Make Users Part of the Process: Involve clinicians and end-users in the development cycle early on. Actively listening to their challenges and integrating their feedback ensures the final product is designed to solve their problems and fits seamlessly into their existing workflow.

References

• Dr. Shannon Decker's LinkedIn
• Etienne Nichols' LinkedIn: Connect with Etienne
• Schema Theory: Discussed as the framework for how adults integrate new information with their existing base of knowledge and experience.

MedTech 101 Section: Pedagogy vs. Andragogy

Pedagogy and Andragogy are two core concepts in education theory that explain how different groups of people learn.

• Pedagogy (Child Learning): This is the traditional model where the teacher is in charge. Learning is directed, sequential, and structured by an authority figure (e.g., a child must learn A before they learn B). The child relies on the teacher for direction and motivation.
• Andragogy (Adult Learning): This model recognizes that adults are fundamentally different learners. Adult learning is self-directed, problem-centered, and motivated by relevance. Adults must understand why they need to know something and how it immediately applies to their lives or work. They also leverage their deep existing experience base (their schema) to evaluate new information.

Why it matters in MedTech: In a fast-paced field like medical devices, requiring an engineer to passively read 40 procedural documents (a pedagogical approach) is inefficient. Using an andragogical approach—by giving the engineer a project, showing them how the procedure solves a real-world problem, and having them practice the task—results in faster adoption, greater compliance, and better performance.

Feedback Call-to-Action

We want to hear from you! Do you use andragogy principles in your training? Have a question about leveraging intrinsic motivation in your team?

Send your feedback, episode reviews, or topic suggestions directly to the Podcast Producer: podcast@greenlight.guru. We read every email and your input helps shape the future of the Global Medical Device Podcast.

Sponsors

This episode is brought to you by Greenlight Guru, the only MedTech-specific platform with both a next-generation QMS and an integrated Electronic Data Capture (EDC) solution.

In an industry where successful training and adoption rely on integrating quality with practical use, Greenlight Guru helps you eliminate disconnected, clunky systems. By integrating your quality processes (QMS) with your clinical data capture (EDC), you ensure your teams are operating on the same source of truth, making it easier for adult learners—from R&D to clinical investigators—to understand and adopt your technology. Get the purpose-built platform that helps you design and build higher quality devices faster. Learn more at greenlight.guru.

Haley explains the three key pillars of reimbursement: coding, coverage, and payment. She delves into the complexities of CPT codes and the significant difference between a temporary Category 3 code and the gold-standard Category 1. The discussion also covers the immense challenges medical device companies face, including the lengthy timeline—sometimes years—to secure payer coverage, which can be a make-or-break factor for startups. The conversation wraps up with a look at how artificial intelligence is beginning to streamline the cumbersome, manual process of patient access and appeals.

Key Timestamps

• 1:45 - The initial challenge of making coverage match medical need.
• 3:30 - The three-part reimbursement pathway: coding, coverage, and payment.
• 5:50 - Navigating CPT codes and the difference between Category 1 and Category 3.
• 10:15 - Common challenges for medical device companies seeking payer coverage.
• 13:20 - The multi-year timeline to achieve Medicare coverage for innovative devices.
• 15:00 - Advice for regulatory and quality professionals on speeding up reimbursement.
• 20:10 - How AI is currently being used in patient access and reimbursement.
• 24:45 - Debating the accuracy of AI and its role in replacing human expertise.

Quotes

"A lot of times patients are not going to be able to pay out of pocket for expensive medical treatments, and a lot of times providers are not going to be able to write off those treatments on their side. So somebody needs to pay for this. And that's usually the health insurance companies..." — Haley King

"I think that for this sort of a use case [AI], you're always going to want some human in the loop... AI has the potential to be super, super powerful in this space, but I think you're always going to want to have human experts involved." — Haley King

Takeaways

• Integrate reimbursement strategy early: Unlike FDA approval, which focuses on safety and efficacy, payers also demand evidence of a device's clinical and economic value. Medical device companies, particularly startups, should integrate reimbursement planning into their pitch decks and product development timelines from the outset.
• Recognize the two-step process: FDA approval is not a golden ticket to reimbursement. Companies must understand the subsequent and often lengthy process of securing coding, coverage, and payment from payers like CMS and private insurance companies, which can take several years.
• Enhance clinical trials for payers: Regulatory and quality professionals can speed up the reimbursement process by designing clinical trials that not only meet FDA requirements but also generate robust data to prove a device's clinical and economic value. This may involve including additional endpoints to justify the cost.
• Harness AI for efficiency, not replacement: AI is a powerful tool for automating the tedious parts of reimbursement, such as sifting through patient records and payer policies. However, it should be viewed as a way to enhance, not replace, the work of human experts who can handle complex edge cases and appeals.
• Be aware of coding complexities: The distinction between a temporary Category 3 CPT code and a permanent Category 1 code is a major hurdle for innovative devices. Companies must be prepared for a potential multi-year journey to prove their device’s value to the American Medical Association (AMA) and payers.

References

• Paxos Health: Haley King’s company, which helps patients and physicians navigate insurance barriers for medical care.
• Current Procedural Terminology (CPT) Codes: The standardized language used by healthcare providers and payers to bill for medical services.
• Study on Payer Coverage: A 2023 study referenced in the episode, with authors including Josh Macaur and Dr. Erin Saxton, that found a nominal time of 5.7 years for innovative medical devices to achieve Medicare coverage.

You can also connect with Global Medical Device Podcast host Etienne Nichols on LinkedIn: https://www.linkedin.com/in/etienne-nichols-824a7114/

MedTech 101: The CPT Code Breakdown

Think of a CPT (Current Procedural Terminology) Code as a unique ID number for a specific medical procedure or service. When a doctor performs a treatment, they use this code to communicate with an insurance company (payer) what they did so they can get paid.

• Category 1 Codes are like the established, official ID numbers. They're for widely accepted procedures with proven clinical value and are typically covered by insurance.
• Category 3 Codes are like temporary ID numbers. They are assigned to newer, innovative procedures that are still being studied. They allow doctors to track the procedure's use, but they don't guarantee that insurance will pay for it. The goal is to collect enough data over time to upgrade to a Category 1 code.

Feedback Call-to-Action

Your feedback helps us create content that matters to you. Have a topic suggestion or a question about this episode? Please reach out to us at podcast@greenlight.guru. We read every email and appreciate your insights!

Sponsors

This episode is brought to you by Greenlight Guru, the only medical device success platform built specifically for MedTech companies. As discussed in this episode, getting your device to market requires more than just a great product; it needs a robust quality system and a clear path to market adoption. Greenlight Guru's QMS and EDC solutions are designed to streamline your development process from concept to commercialization, helping you secure the data needed for both FDA approval and payer reimbursement. To learn more, visit www.greenlight.guru.

Mohamad Foustok introduces the concept of "zero trust" and the critical importance of designing for security across the entire product lifecycle, from initial concept to post-market surveillance. The discussion clarifies that cybersecurity is not limited to network-connected devices but applies to any medical device with a software function, regardless of its connectivity. They also touch on the historical context of FDA guidance, noting a significant shift in recent years that has raised the regulatory bar and put a greater emphasis on robust cybersecurity documentation.

The guests provide actionable advice for MedTech professionals, stressing the value of a balanced approach that integrates security and functionality from day one. They explain that a well-thought-out process, though seemingly slower at the outset, ultimately saves time and resources by preventing costly and time-consuming redesigns later on. This episode serves as a vital guide for anyone looking to build a secure and compliant medical device in today's evolving regulatory landscape.

Key Timestamps

• [01:50] Common pitfalls in developing SaMD, including overlooking regulatory guidance like IEC 62304.
• [03:20] The critical mistake of treating cybersecurity as an afterthought in product development.
• [05:00] Who cybersecurity applies to beyond software, including patients, manufacturers, and supply chains.
• [06:30] The FDA's stance on cybersecurity for any device with a software function, even if not network-connected.
• [08:00] A discussion on "reasonable assurance of cybersecurity" and what it means for manufacturers.
• [10:00] The "zero trust" principle and why you should never assume a network is secure.
• [14:00] How hospitals and other stakeholders are demanding more rigorous cybersecurity standards.
• [15:40] The ideal process for a "security-first" development lifecycle.
• [21:00] Why rushing development without a proper architecture can lead to significant delays and cost overruns.
• [23:00] A brief history of FDA's cybersecurity guidance and the major shift in 2023.

Quotes

"Software as a medical device ultimately is a medical device, and so you want to be developing it from the get-go with that mindset." — Jose Bohorquez

"Security can't be an afterthought. You have to consider security at the inception of your approach to a product." — Mohamed Fustok

Takeaways

• A "Security-First" Mindset is Essential: Integrate cybersecurity from the initial architectural phase of your project. This proactive approach saves significant time and money by avoiding costly redesigns and delays later in the development process or after an FDA submission.
• Cybersecurity is for All Software-Driven Devices: Don't assume that only cloud-connected devices need cybersecurity documentation. The FDA requires documentation for any device with a software function, including embedded systems and programmable logic, even if it's not connected to a network.
• Regulatory Compliance is a Process, Not a Document: The FDA is not just looking for a checklist of documents; they want to see a well-defined and consistently followed process for how you build and secure your software. This includes a "reasonable assurance of cybersecurity" that stands up to scrutiny.
• Hospitals are Your New Regulators: Beyond FDA compliance, be prepared for hospitals and other buyers to conduct their own rigorous cybersecurity audits. A strong cybersecurity posture is becoming a key differentiator and a prerequisite for market access.

References

• IEC 62304: The international standard for medical device software life cycle processes. It is a foundational requirement for developing compliant medical software.
• FDA Guidance Documents: Specific documents from the U.S. Food and Drug Administration that provide detailed requirements for software as a medical device (SaMD) and cybersecurity.
• Etienne Nichols' LinkedIn: For more insights and connections in the medical device industry, connect with Etienne Nichols. [https://www.linkedin.com/in/etienne-nichols-105151241/]

MedTech 101

Zero Trust: A cybersecurity principle that means you should never automatically trust anything inside or outside of your network perimeter. Instead, every access request must be verified before granting access. Think of it like a strict security guard who checks everyone's ID, even if they claim to work there. In a hospital setting, this means a medical device should not assume the hospital's Wi-Fi is secure; it should treat every connection as potentially hostile and build in its own protections. This is in contrast to the old model where everything inside the network was trusted by default.

Feedback Call-to-Action

We love to hear from our listeners! Your feedback helps us create content that is most valuable to you. Please send your comments, topic suggestions, and guest recommendations to podcast@greenlight.guru. We read and respond to every email personally.

Sponsors

This episode of the Global Medical Device Podcast is brought to you by Greenlight Guru. In a world where regulatory requirements for software are constantly changing, having a robust and agile Quality Management System is non-negotiable. Greenlight Guru's Medical Device QMS & EDC solutions are purpose-built to help you navigate these complexities, from initial design through post-market surveillance, ensuring your SaMD and other medical devices are secure, compliant, and ready for market. Visit their website to learn how their solutions can streamline your entire development process.

Stuart Grant’s discussion on the front end of innovation highlights the importance of deeply understanding the user and the environment in which a device will be used. He introduces a number of tools and techniques, such as the Pugh Matrix and the NVivo software, to help teams transition from a broad exploration of ideas to a focused, viable product concept. Stuart explains that while the front end may seem "fuzzy," it can be a systematic process that uncovers the true clinical and market needs that will determine a product's success. He emphasizes that the most successful devices aren't just incrementally better, but are born from a deep understanding of customer insights.

This episode is an essential guide for anyone involved in MedTech innovation, from academic researchers to seasoned engineers. Stuart's insights challenge the conventional reliance on key opinion leaders and provide a framework for a more holistic, user-centric approach. He outlines how to identify and interpret subtle user behaviors, from workarounds and unconventional uses to unspoken frustrations, all of which are critical for developing a truly impactful and user-friendly medical device. Whether you're at the very beginning of a project or looking to improve your current innovation process, this episode provides actionable strategies to bridge the gap between a great idea and a marketable product.

Key Timestamps

• (2:00) Defining the "Front End": Stuart explains what the front end of innovation is and why its name has evolved from the "fuzzy front end."
• (8:00) The Double Diamond Model: An explanation of the UK Design Council's Double Diamond, illustrating the divergent and convergent phases of problem-solving.
• (12:30) Common Pitfalls: Discussing the three critical questions to answer: Is there a market (viability)? Is the technology possible (feasibility)? Do users want it (desirability)?
• (15:00) Balancing Creativity and Structure: The roles of different team members and how to manage the creative (divergent) and critical (convergent) phases of innovation.
• (21:00) 10 Ways to Find User Insights: Stuart breaks down the specific techniques and red flags to look for when observing users, including workarounds, affordances, and areas of disjuncture.
• (26:00) The Problem with KOLs: Why relying solely on key opinion leaders can be a mistake and the importance of observing a wider range of users.
• (30:00) Triggers of Use: How unconventional uses of a device can reveal new product opportunities.

Standout Quotes

"A craftsman will build you exactly what you ask for. An artist will build you what you didn't know you need." - Etienne Nichols

"You don't just do what the customer says because that could lead to a terrible product." - Stuart Grant

Takeaways

• Observation is Key: Go beyond interviews. The most valuable insights come from observing users in their natural environment, such as a surgeon in the operating room. Pay attention to "workarounds" or unconventional uses, as these often reveal critical unmet needs.
• Balance Divergence and Convergence: Use a structured approach like the Design Council's Double Diamond to manage the innovation process. Start with a broad, creative phase to gather information and ideas (divergence), then narrow down and refine them into a concrete solution (convergence).
• Assemble a Diverse Team: The best innovation teams include a mix of skill sets, from engineers and designers to marketers and clinical representatives. Each function plays a critical role in controlling the process and ensuring the product is viable from multiple perspectives.
• Look for Disjuncture: Be on the lookout for inconsistencies between what a user says and what they actually do. This "disjuncture" can reveal hidden pain points and lead to profound insights that others might miss.
• Don't Over-Rely on KOLs: While key opinion leaders offer valuable expertise, their extensive experience can cause them to overlook usability issues that affect the majority of users. Include a diverse range of users in your research to ensure your product is accessible and effective for the broader market.

References

• Design Council Double Diamond: A visual representation of the design process, emphasizing phases of divergent and convergent thinking.
• Donald Norman, "The Design of Everyday Things": A foundational book on human-centered design, which discusses concepts like affordances.
• Pugh Matrix: A tool used to compare and evaluate multiple design concepts against a set of criteria.
• Etienne Nichols's LinkedIn Profile

MedTech 101: The Double Diamond

Imagine you have a new idea for a medical device. Where do you start? The Double Diamond model is a simple but powerful framework to guide you. Think of the first diamond as the "problem space." You start by diverging, or expanding your view, to explore every angle of a problem. This is like brainstorming—you collect a wide range of information about the user, the environment, and the clinical need without judgment. Then, you converge on a single, clear problem statement.

The second diamond is the "solution space." You diverge again, this time to come up with many different ideas and concepts to solve the problem you've defined. You're thinking creatively about all the possible solutions. Finally, you converge one last time to select and refine the best solution, turning it into a concrete product concept. This process ensures you're not just solving a surface-level issue but a real, well-defined problem with a well-considered solution.

Feedback Call-to-Action

What are your thoughts on the "front end" of innovation? Have you experienced any of the user insights Stuart discussed? We'd love to hear your stories and questions. Email us at podcast@greenlight.guru with your feedback or to suggest a topic for a future episode. We read every email and will respond to you personally.

Sponsors

This episode is brought to you by Greenlight Guru, the only medical device success platform designed specifically for MedTech companies. Their MedTech Suite, including both QMS & EDC solutions, is built to address the unique challenges of medical device product development and quality management. Just as Stuart Grant highlighted the importance of a structured process to go from an idea to a marketable product, Greenlight Guru helps you manage that entire journey with purpose-built software. To learn how Greenlight Guru can help you navigate the entire product lifecycle, visit www.greenlight.guru.

Steve emphasizes the importance of moving beyond a great idea to build a viable business. He outlines the foundational mistakes that sink over 75% of startups, from emotional attachment to non-viable concepts to underestimating the time and financial commitment required. He introduces his “greenhouse score” system, an objective, data-driven tool designed to help founders evaluate their business idea against global competition, urging them to "kill their ideas early" if they aren't built for success.

The conversation also touches on the unique challenges facing first-time founders, including the critical decision of who should lead the company. Steve advises against a "have-a-go-hero" mentality and highlights the value of bringing in experienced leadership to avoid costly mistakes. He stresses that true success lies in being "needs-based, not product-based," focusing on solving a core problem rather than becoming overly attached to a specific solution. The episode concludes with a warning about protecting intellectual property (IP) and the costly mistake of sharing proprietary information prematurely.

Key Timestamps

• 00:02:13 The origin story of Steve's MedTech startup course.
• 00:04:58 The #1 reason MedTech startups fail: A good idea isn't always a good business.
• 00:08:54 The greenhouse score and MedTech AI advisor for objective business idea validation.
• 00:11:09 Why entrepreneurship is a "wide open field" and how to find a path.
• 00:12:00 The importance of "Location, Location, Location" for MedTech startups.
• 00:13:58 The MedTech Survival Guide book and life lessons learned.
• 00:17:02 Should a first-time founder be the CEO?
• 00:18:10 How to find and compensate an experienced CEO.
• 00:20:45 Why you must be needs-based, not product-based.
• 00:22:47 The difference between a business and an orphan or philanthropic project.
• 00:23:53 The risk of destroying your IP before you even get started.

Quotes

• "Every idea is good, but not every idea is a good business... some of them are just really interesting tech that's trying to look for a home." - Steve Bell
• "Most likely thing for most companies is the idea you go in with is not the idea you come out with... You need to be needs-based, not product-based." - Steve Bell

Takeaways

• Validate Your Idea Objectively: Don't rely on gut feelings. Use data-driven tools to assess your business idea's viability. If your "greenhouse score" is low, don't abandon the need—pivot the solution or fix the weaknesses.
• Stack the Deck in Your Favor: Simple, logical choices can significantly increase your odds of success. This includes selecting a strategic business location and prioritizing a strong team over a lone "have-a-go-hero" founder.
• Hire Experienced Leadership: A first-time founder should rarely be the CEO. Bringing in a seasoned professional with C-suite experience can save millions of dollars and years of development, as they bring invaluable scar tissue and a network of investors.
• Protect Your Intellectual Property: Be mindful of how you share information. Publishing abstracts or presenting data prematurely can destroy your ability to patent your invention. Treat your IP like a "billion-dollar map" and guard it accordingly.
• Focus on the "Need," Not the "Product": Your passion should be for solving a problem, not for a specific device. Your initial product idea may not be the one that succeeds, but your mission to solve the underlying clinical need should remain constant.

References

• Steve Bell's MedTech Course: An extensive online course with over 100 videos designed to guide MedTech entrepreneurs from concept to exit.
• 
  
• MedTech Advisor AI: An upcoming tool that uses an algorithm to provide an objective "greenhouse score" for MedTech business ideas.
• Greenlight Guru: Provides both a QMS and an EDC solution to help medical device companies of all sizes manage their product development and quality processes.
• Etienne Nichols' LinkedIn: https://www.linkedin.com/in/etienne-nichols-10705174/

MedTech 101: The Entrepreneur's Mindset

In MedTech, a startup is a new company in its early stages, often focused on a single breakthrough technology. But as Steve Bell explains, a great technical idea isn't enough; you need a great business idea. This means the company must have a clear path to profitability and market sustainability.

Think of it this way: a car enthusiast might build a highly advanced, custom race car in their garage (a great technical idea). But if it costs a fortune to build and can only compete in a small, niche racing circuit with no prize money, it's not a viable business. An entrepreneur, on the other hand, would look at a market need—say, a demand for affordable, electric delivery vehicles—and then design a vehicle to meet that need, ensuring there's a clear way to make a profit. The entrepreneur focuses on the market need first, not just the technology.

Feedback Call-to-Action

What are your biggest challenges as a MedTech entrepreneur? Email us your questions or topic suggestions at podcast@greenlight.guru. We read every message and value your input! Your feedback helps us shape future episodes and provide the most relevant content for the MedTech community.

Sponsors

This episode is brought to you by Greenlight Guru. Launching a MedTech startup is a marathon, not a sprint, and managing your quality and clinical data shouldn't slow you down. Greenlight Guru offers a modern, intuitive QMS & EDC solution specifically for medical device professionals. Our software helps you streamline your product development, ensuring you can focus on building a successful business without getting bogged down by compliance issues. Greenlight Guru provides the tools you need to stay on track from concept to market and beyond.

Josh delves into the unique investment philosophy of Solas BioVentures, which is an operator-led firm that provides hands-on guidance to early-stage startups. He introduces the firm's core "dote, goat, float, and moat" framework, which evaluates a company's therapeutic efficacy, management team, economic viability, and intellectual property. The discussion provides a candid look at how venture capitalists assess risk and make investment decisions, highlighting the importance of building a strong, emotionally intelligent team and demonstrating a clear path to market.

The conversation also explores practical strategies for startups to de-risk their investment proposition. Josh offers insights on how companies can use a pre-submission to get crucial feedback from the FDA, and how leveraging the right advisory board can instill confidence in potential investors. He explains the value of bringing in key opinion leaders and how a well-structured clinical trial, with thoughtfully designed inclusion and exclusion criteria, is essential for proving a technology's safety and efficacy.

Key Timestamps

• 1:02 - Josh's transition from medicine to venture capital.
• 7:27 - The unique, operator-led investment approach of Solus Bio Ventures.
• 12:47 - The "dote, goat, float, moat" framework for evaluating startups.
• 15:02 - What makes a great management team ("the goat").
• 24:43 - De-risking strategies for early-stage MedTech companies.
• 27:55 - The importance of regulatory discussions with the FDA.
• 30:13 - Building and compensating a strong advisory board.

Quotes

• "I call that leveraged change. I try to change that fulcrum of not just one patient at a time like I felt like in clinical medicine, but advocating and changing the lives of hundreds of people by getting these drugs and devices to market." - Joshua Eckelberry

Takeaways

• Focus on the team: Investors, particularly at the early stage, place significant emphasis on the management team's experience, emotional intelligence, and ability to navigate challenges. Past success and a positive, collaborative culture are key indicators of future performance.
• De-risk early and strategically: To attract early-stage capital, companies must proactively address key risks. This includes securing strong intellectual property, proving therapeutic efficacy, and engaging with regulatory bodies like the FDA through pre-submissions to gain confidence.
• Build a knowledgeable advisory board: A well-vetted board of advisors with a strong reputation and deep industry knowledge—particularly in areas like reimbursement and regulatory affairs—can be a major confidence booster for investors.
• Understand the "Dote, Goat, Float, Moat" framework: Companies should be prepared to address these four pillars: Dote (therapeutic efficacy), Goat (management team), Float (economics/reimbursement), and Moat (intellectual property).
• Embrace the conversation: Early-stage investors are often more accessible than founders might assume. Reaching out and engaging with firms like Solus Bio Ventures can lead to valuable feedback and potential opportunities.

References

• Solas BioVentures: The investment firm where guest Josh Eckelberry serves as Principal.
• Etienne Nichols' LinkedIn: https://www.linkedin.com/in/etiennenichols/
• Greenlight Guru: A medical device quality management software (QMS) and electronic data capture (EDC) platform for a medical device company's entire product lifecycle.

MedTech 101

• Venture Capital (VC): A form of private equity financing provided by venture capital firms or funds to startups, early-stage, and emerging companies that have been deemed to have high growth potential. VCs invest in exchange for an equity stake in the company.
• Pre-submission (Pre-Sub): A formal request submitted to the FDA to receive feedback on a medical device before a marketing submission (e.g., 510(k), PMA). This allows a company to de-risk its regulatory pathway by getting clarity and guidance on clinical study design, quality system requirements, and the most appropriate regulatory path.
• Intellectual Property (IP): Intangible creations of the mind—such as inventions, designs, and patents—that are legally protected from being copied or used by others without permission. In MedTech, this is often a company’s most valuable asset and provides a competitive advantage.

Feedback Call-to-Action

We want to hear from you! If you have a question or a topic you'd like us to cover, please reach out to us at podcast@greenlight.guru. We read every email and respond personally. Your feedback helps us create the content you want to hear.

Sponsors

This episode is brought to you by Greenlight Guru, the only medical device success platform that offers both QMS & EDC solutions. Greenlight Guru helps medical device professionals get their devices to market faster and keep them on the market by providing a purpose-built software platform that streamlines the product lifecycle. From design controls to risk management and post-market surveillance, Greenlight Guru is your partner in improving the quality of life.

From there, Edwin transitioned into manufacturing, where he applied his skills in teaching electronics and later, quality management. He was trained by renowned quality gurus like Joseph Juran and learned about concepts like Six Sigma and Kaizen from companies like Motorola and Toyota. These experiences, which focused on process improvement, cost of quality, and efficiency, laid a critical foundation for his future work.

Edwin connects these seemingly disparate experiences to his pivotal role in medical device risk management. He explains how issues in manufacturing—such as supplier quality, process capability, and yield—directly impact patient safety and a company's financial bottom line. This holistic view, blending technical expertise, quality principles, and a deep understanding of manufacturing processes, ultimately led him to the committee that developed the ISO 14971 standard.

Key Timestamps

• 01:52 - Edwin's military background as a submariner and electronics technician, and how he helped build a missile sub from scratch.
• 04:27 - The transition from military to a career in manufacturing and quality management, including his training under Joseph Juran.
• 10:59 - Edwin’s role in supplier quality and his lessons learned from working with a wide range of suppliers.
• 15:48 - The impact of Kaizen projects and other modern manufacturing techniques on efficiency and quality.
• 18:18 - An incredible story of a supplier with an ownership mindset that maintained delivery schedules after a factory fire.
• 18:59 - Connecting manufacturing experience and quality principles to the fundamentals of risk management.
• 20:46 - The crucial link between quality, patient safety, and a company’s financial success.
• 25:28 - How to apply statistical and manufacturing improvement tools in the medical device industry.
• 27:20 - The value of hands-on experience and a holistic understanding of a product's lifecycle.
• 30:09 - How Edwin’s diverse experiences ultimately led him to a key role in developing ISO 14971.

Quotes

• "If you want to think about cost of quality, it, you know, what is the cost to the company of this? You've got to have safe and effective medical devices." - Edwin Bills
• "When you get a statistician to help you improve your manufacturing processes, you want an industrial statistician... When you get to the clinical trials, that person's not the right person to have. You want a research statistician." - Edwin Bills

Takeaways

• Manufacturing Quality is Risk Management: The principles of quality improvement, process control, and supplier management—learned in high-volume manufacturing—are directly applicable to mitigating risks in medical devices. A high-quality, reliable process inherently reduces the likelihood of product failures that could harm patients.
• Prioritize Quality Over Price: As Edwin's experience with the electric motor supplier shows, prioritizing the lowest cost can lead to significant issues, non-conformances, and a higher overall cost of poor quality. A supplier focused on quality and delivery will ultimately save a company money and protect its reputation.
• Seek Hands-On Experience: Knowing a product "down to the nuts and bolts" provides invaluable insight. This can be achieved through cross-functional training, allowing engineers and managers to understand the practical challenges of manufacturing and assembly, leading to more robust and safer designs.
• Right Tool, Right Time: The medical device industry can improve by adopting modern statistical and process improvement tools like Kaizen and Six Sigma. However, it's crucial to select the right kind of expert for the specific task at hand, whether it's process improvement or clinical trial design.
• Holistic Approach to Risk: Effective risk management goes beyond just patient safety. It must consider the full spectrum of risks, including financial and reputational damage, which are often the direct result of a failure to manage quality and safety risks effectively.

References

• Joseph M. Juran: A 20th-century quality management pioneer. His work on the "Juran Trilogy" (quality planning, quality control, quality improvement) and the concept of the "cost of quality" were foundational to modern quality systems.
• Six Sigma: A set of techniques and tools for process improvement, originally developed by Motorola. It aims to reduce defects and variation to near-perfect levels.
• Kaizen: A Japanese term for "change for the better" or "continuous improvement." It is a business philosophy focused on improving all functions and involving all employees.
• ASQ (American Society for Quality): A global organization dedicated to quality management and improvement.
• Link to Etienne Nichols' LinkedIn: https://www.linkedin.com/in/etienne-nichols-pmp-csm-a1851b14/

MedTech 101

• CPK (Process Capability Index): CPK is a statistical measure that tells you how well a manufacturing process is performing relative to its design specifications. A higher CPK value means the process is more reliable and consistently produces parts that meet requirements. A CPK of 1.0 means the process is just barely capable of meeting the specs, while a CPK of 2.0 (associated with Six Sigma) means it’s highly capable and produces very few defects.
• Kaizen: Think of Kaizen like a never-ending team effort to make small, smart improvements. Instead of waiting for a big problem to fix, everyone from the CEO to the factory floor worker looks for tiny ways to make things a little bit better, a little bit faster, or a little bit safer every single day.

Feedback Call-to-Action

We value your insights! What topics would you like us to explore next? Share your feedback, suggest future guests, or leave us a review. You can reach us directly at podcast@greenlight.guru. We read every message and look forward to hearing from you.

Sponsors

This episode is brought to you by Greenlight Guru, the only medical device success platform designed specifically for MedTech companies. Their flagship QMS and EDC solutions are helping MedTech professionals get products to market faster, and with less risk. To learn more about how Greenlight Guru's solutions can streamline your quality and data processes, visit www.greenlight.guru.

Lesley highlights that true influence and buy-in don’t come from simply explaining things well, but from actively listening and making others feel heard. The discussion touches on common pitfalls, such as using excessive jargon, over-explaining, and failing to understand the listener's perspective. Lesley emphasizes the importance of building trust and psychological safety, which allows for open communication and the ability to ask clarifying questions without fear. She shares practical strategies, like paraphrasing to confirm understanding and moving from a "broadcast" mindset to one of curious listening.

The conversation concludes with a look at the limits of traditional training, which often focuses on information over action and fails to address personal habits and emotional intelligence. Lesley describes how her coaching practice provides a personalized space for professionals to think through their specific challenges and discover their own solutions. She advocates for simple, plain language and encourages a shift from fear-based interactions to curiosity-driven ones, underscoring that the core of effective communication is a human-centric approach.

Key Timestamps

• [02:52] - The PR Problem: Lesley addresses why skilled professionals in quality and regulatory roles often struggle to be heard, linking it to their non-direct authority and a tendency to prioritize correctness over relationships.
• [06:34] - The Buy-in Breakthrough: The difference between being understood and making someone feel understood is explored, revealing that true buy-in hinges on empathy and listening.
• [09:34] - Communication Blind Spots: This segment uncovers common, subconscious behaviors that undermine communication, such as using too much jargon, over-explaining, and failing to consider the audience's knowledge.
• [14:17] - The Power of Admitting 'I Don't Know': Etienne and Lesley discuss how acknowledging a lack of understanding can build trust and demonstrate self-awareness, countering the fear of appearing "dumb."
• [16:42] - Fear vs. Curiosity: Etienne shares his perspective on curiosity as the opposite of fear and a powerful tool for overcoming communication anxieties.
• [18:12] - Why Training Fails: The limitations of traditional corporate training are examined, highlighting its focus on information rather than the personalized, action-oriented work required for true behavioral change.
• [25:39] - The Coaching Advantage: Lesley explains how coaching helps professionals solve their own problems and gain clarity by creating a dedicated space for focused thinking and reflection.

Quotes

• "Buy-in isn't about whether people understand; it's about whether people feel understood." — Lesley Worthington
• "Curiosity... I think the opposite of fear is curiosity." — Etienne Nichols

Takeaways

• Shift from Correctness to Connection: The most effective medical device professionals understand that their influence isn't solely based on being technically correct. Instead, they build strong relationships by focusing on making others feel heard, which ultimately encourages buy-in.
• Plain Language is a Global Asset: In an increasingly globalized industry, avoiding jargon and using plain language is crucial. This not only enhances clarity for non-specialists but also helps prevent miscommunication across different languages and cultures.
• Listening as a Strategic Tool: Listening isn't passive; it's an active, strategic skill. By asking clarifying questions and paraphrasing what you've heard, you can build trust and ensure mutual understanding, leading to smoother project execution and a stronger culture of quality.
• Identify Your Communication Blind Spots: Many professionals have communication habits—like over-explaining or using jargon to prove credibility—that unknowingly undermine their effectiveness. Recognizing and addressing these "hidden things" is the first step toward becoming a more influential leader.
• Action Over Information: While traditional training provides valuable information, true change comes from putting that knowledge into practice. Personalized coaching and self-reflection are powerful tools for addressing specific, real-world communication challenges that generic courses cannot.

References

• FDA QMS Regulation (QMSR): The episode references the FDA's new Quality Management System Regulation (QMSR) and its preamble, which includes expectations for a "culture of quality."
• Etienne Nichols's LinkedIn: For more insights and connections within the medical device industry, you can connect with Etienne Nichols on LinkedIn: https://www.linkedin.com/in/etienne-nichols/.
• Lesley Worthington's LinkedIn: To learn more about executive coaching and communication, connect with Lesley Worthington on LinkedIn.

MedTech 101 Section

Curse of Knowledge: This psychological bias describes the difficulty a person has in thinking about a problem from the perspective of a less-informed person. In the context of the medical device industry, a quality or regulatory professional with a deep understanding of a topic (like a CAPA or a 483) might mistakenly assume that everyone else on the team shares the same level of knowledge. This leads to the use of jargon and a lack of clear explanation, which can confuse others and hinder collaboration. The "curse" is broken by consciously stepping back and using simple, everyday language that is accessible to all.

Feedback Call-to-Action

What are your biggest communication challenges in MedTech? Share your thoughts and topic suggestions with us. We want to hear from you! Please send your feedback, questions, or ideas directly to us at podcast@greenlight.guru. Your input helps us create the content you need most.

Sponsors

This episode is brought to you by Greenlight Guru, the only medical device QMS and EDC platform designed specifically for MedTech professionals. Greenlight Guru's end-to-end solution helps you streamline your quality processes and clinical trials, ensuring compliance and accelerating your time to market. To learn more about how Greenlight Guru's Quality Management Software (QMS) and Electronic Data Capture (EDC) solutions can help your company, visit www.greenlight.guru.

Beth highlights that the key to a strong partnership is open communication and mutual respect, moving away from the "quality as a police force" mentality. She emphasizes that quality is not just a department but a company-wide mindset—a concept she calls "small Q quality." The discussion provides practical insights on how project managers and quality professionals can work together effectively, ensuring that processes are flexible yet compliant.

They also explore how language and tools can either help or hinder this collaboration. By reframing conversations to focus on shared goals like risk mitigation and efficiency, and by adopting user-friendly QMS solutions like Greenlight Guru's, teams can achieve better engagement and compliance. Beth shares a personal anecdote about turning a skeptic into a quality champion by simply explaining the "why" behind a procedure, underscoring the power of education and trust in fostering a culture of quality.

Key Timestamps

• 00:02:54 - Defining a culture of quality and the friction points in implementation.
• 00:03:21 - The problem with "big Q" and "small Q" quality and why language matters.
• 00:07:05 - The ideal relationship between a project manager and a quality professional.
• 00:10:34 - The analogy of quality as a safety guardrail for the company.
• 00:11:14 - Expanding the scope of risk management beyond patient harm.
• 00:14:53 - Strategies for overcoming resistance and low adoption of new quality tools.
• 00:17:43 - The importance of involving quality professionals early in the proof-of-concept phase.
• 00:19:30 - Tailoring communication to different departments to enhance engagement.
• 00:21:21 - Beth's story about converting a skeptic into a quality champion by explaining the "why."
• 00:24:42 - The critical role of digital solutions in streamlining change orders and design controls.

Quotes

• "Quality is doing the right thing when nobody's watching."
• "Quality can be a police force or they can be a partner. We want to make sure they're a partner." - Etienne Nichols

Takeaways

• Foster a Culture of Collaboration: Shift the mindset from quality as a policing function to a collaborative partnership. Open communication and trust between project managers and quality professionals are essential for success and compliance.
• Explain the "Why": Rather than dictating procedures, take the time to explain the purpose and regulatory justification behind quality processes. When people understand the "why," they are more likely to adopt and champion the system.
• Flexibility is Key: A rigid QMS can lead to frustration and workarounds. Build flexibility and risk-based decision-making into your processes from the start, allowing for deviations when justified without compromising safety or compliance.
• Involve Quality Early: Bringing quality professionals into the R&D and proof-of-concept phases ensures that early-stage documentation is robust and controlled. This streamlined approach prevents issues and rework later in the development cycle.
• Leverage Modern Tools: Modern Electronic Quality Management Systems (EQMS) like Greenlight Guru's QMS and EDC solutions can transform tedious manual tasks—such as managing change orders and design controls—into an efficient, traceable process, saving time and reducing errors for the entire team.

References

• ISO 13485: The international standard for quality management systems specific to medical devices.
• 21 CFR Part 820: The FDA's Quality System Regulation for medical devices.
• ISO 14971: The international standard for applying risk management to medical devices.
• IEC 62304: The standard for the software life cycle process for medical device software.
• Etienne Nichols's LinkedIn: https://www.linkedin.com/in/etiennenichols/

MedTech 101

Quality Management System (QMS): A QMS is a structured set of processes and procedures that a medical device company uses to ensure their products meet regulatory requirements and customer expectations. Think of it as the company's "operating manual" for quality. It outlines everything from design controls and risk management to manufacturing, change orders, and post-market surveillance. While historically paper-based, modern companies are moving toward electronic QMS (EQMS) solutions for greater efficiency and traceability.

We Want Your Feedback!

Thank you for tuning in to the Global Medical Device Podcast. We hope this episode provided valuable insights into the crucial collaboration between project management and quality.

Have a topic you'd like us to cover? Your feedback helps us create content that is relevant and useful to you. Please send your suggestions, comments, and questions to our team at podcast@greenlight.guru. We read every message and look forward to hearing from you.

The conversation delves into what truly matters in an EDC platform, such as intuitive design, speed of implementation, and the ability to handle repeatable processes. Christine shares that while some vendors may offer "bells and whistles," the core value lies in a lean, efficient system tailored to medical device trials. They also touch on the importance of involving all stakeholders, including site users like clinicians and healthcare professionals, to ensure system adoption and maintain data integrity.

Finally, the discussion explores how an EDC system can help CROs win more business. Christine explains that having a scalable, pre-validated solution and a vendor that actively supports business development can be a significant advantage. They also cover the essential compliance features for global trials, such as FDA 21 CFR Part 11 and ISO 14155, and the growing role of hybrid and decentralized trials. Christine's final advice to CROs is to "do your due diligence" and select a solution that's a true partner for long-term success.

Key Timestamps

• 00:02:39 - Biggest mistakes CROs make when choosing an EDC.
• 00:03:00 - The importance of future planning and scalability.
• 00:04:40 - The value of post-sales support and avoiding hidden fees.
• 00:05:31 - Essential features versus "vendor noise" and unnecessary bells and whistles.
• 00:08:11 - The analogy of a "battleship" vs. a "ninja" in problem-solving.
• 00:09:13 - Identifying key stakeholders for successful EDC implementation.
• 00:11:17 - Challenges and strategies for engaging healthcare professionals.
• 00:13:31 - When to start looking for an EDC solution and the typical timeline.
• 00:15:44 - The onboarding process and what successful companies do in the first few months.
• 00:18:39 - How CROs can use an EDC solution to win more business.
• 00:20:52 - Global compliance considerations (FDA, EU MDR) for EDC platforms.
• 00:23:36 - Features CROs think they need but don't (e.g., QMS integration).
• 00:26:03 - Adapting to hybrid and decentralized trials.
• 00:27:22 - The key takeaway: do your due diligence and seek a true partner.

Quotes

"I would say the biggest issue is lack of due diligence... they're not necessarily thinking down the line, 'how is this going to scale with this specific company that they're working with?'"

"The bitterness of poor quality remains long after the sweetness of low price is forgotten."

Takeaways

1. Prioritize Scalability and Long-Term Planning: Don't choose an EDC solution just for a single pilot study. Evaluate whether the platform can handle the complexity and size of pivotal and post-market studies to avoid costly transitions in the future.
2. Look for True Partnership, Not Just a Vendor: A successful relationship with an EDC provider goes beyond the initial sale. Seek a vendor with strong post-sales support and a willingness to collaborate on business development initiatives to help you win more sponsor business.
3. Ensure a User-Friendly Design for All Stakeholders: An EDC system is only as good as the data entered into it. Selecting an intuitive, easy-to-use platform is crucial for ensuring adoption by clinical operations teams, data managers, and, most importantly, site users like clinicians and healthcare professionals.
4. Confirm Global Compliance and Validation Capabilities: For CROs supporting a variety of trials, it is essential to select an EDC platform that is pre-validated and compliant with global regulations like FDA 21 CFR Part 11 and ISO 14155 for EU MDR.
5. Focus on Core Functionalities Over "Bells and Whistles": Many platforms offer features that look good but are rarely used. A lean, purpose-built solution with essential functionalities like remote data entry, ePRO (electronic Patient Reported Outcomes), and efficient reporting is often more valuable than a system overloaded with unnecessary features.

References

• ISO 14155:2020 - Clinical investigation of medical devices for human subjects — Good clinical practice. This standard is referenced as a key compliance framework for medical device clinical trials, particularly in the European Union.
• FDA 21 CFR Part 11 - The part of the Code of Federal Regulations that sets forth the criteria under which the FDA considers electronic records, electronic signatures, and handwritten signatures executed to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper.
• Etienne Nichols's LinkedIn - https://www.linkedin.com/in/etiennenichols/

MedTech 101

What is a Clinical Research Organization (CRO)?

A Clinical Research Organization (CRO) is a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. Think of a CRO as a specialist that a medical device company hires to manage a clinical trial. They handle everything from designing the study and recruiting participants to collecting and analyzing data, allowing the device company to focus on its core business.

What is an Electronic Data Capture (EDC) system?

An Electronic Data Capture (EDC) system is a software platform used in clinical trials to collect, manage, and report patient data. Instead of using paper forms, researchers enter data directly into a secure electronic database. This makes the data easier to share, reduces errors, and speeds up the entire clinical trial process. It’s like moving from a paper filing system to a digital spreadsheet, but with built-in security and compliance features specifically for clinical research.

Feedback Call-to-Action

We want to hear from you! What topics would you like us to cover on future episodes of the Global Medical Device Podcast? Your feedback helps us create content that is most valuable to you. Send your suggestions, feedback, and questions to podcast@greenlight.guru. We read and respond to every email personally.

Sponsors

This episode is brought to you by Greenlight Guru, the only MedTech-specific QMS & EDC solution. Greenlight Guru helps medical device companies and CROs streamline their entire product lifecycle and clinical trial processes. By providing a modern, purpose-built platform for both Quality Management Systems (QMS) and Electronic Data Capture (EDC), Greenlight Guru ensures you have the tools to manage your clinical data and maintain compliance from a single source of truth. To learn how Greenlight Guru can accelerate your journey, visit www.greenlight.guru.

Marina emphasizes that biocompatibility is not an isolated task but must be fully integrated into a company's quality management system (QMS). She explores the connection between biological safety and key QMS processes such as change management, post-market surveillance, and CAPA. The conversation also touches on the shift from a reactive to a proactive mindset in the industry, driven by new regulations like the latest revision of ISO 10993-1.

Using real-world examples, Marina illustrates the importance of considering long-term patient exposure and cumulative effects. She provides clear explanations of complex concepts like the difference between extractables and leachables. Her advice to MedTech professionals is to always be curious, ask questions, and prioritize communication across all teams to ensure the safety and efficacy of medical devices.

Key Timestamps

• 01:37 - Importance of a Biological Evaluation Plan and in-depth data analysis
• 03:48 - The need for critical thinking in biocompatibility, highlighted by the silver ion example
• 06:03 - How a chemistry background informs a deeper understanding of materials
• 08:06 - Real-world examples of biocompatibility risks from the Netflix documentary, The Bleeding Edge
• 11:20 - Discussion on cumulative effects and long-term exposure to materials
• 12:56 - Applying a risk-based approach beyond standard tables
• 15:39 - The difference between extractables and leachables
• 18:18 - Integrating biocompatibility into the QMS (change management, CAPA, post-market surveillance)
• 22:01 - The shift from reactive to proactive biocompatibility approaches
• 23:55 - How to explain complex biocompatibility concepts to non-technical teams

Quotes

• "Biocompatibility is not a bubble. It must be integrated into the quality management system." - Marina Daineko
• "Don’t be shy and ask the questions. Stay curious... and communicate." - Marina Daineko

Takeaways

• Go Beyond the Checklist: A biological evaluation plan and critical thinking are essential. Don't rely solely on standard pass/fail tests; analyze raw data and question unexpected results, as seen in the silver ion example.
• Assess Cumulative Risk: For long-term or implanted devices, consider the cumulative effect of chemicals that may leach from the device over time. Proactive risk management should account for this long-term exposure.
• Integrate Biocompatibility into the QMS: Biocompatibility should not be treated as a standalone task. It must be integrated with core QMS processes like change management, CAPA, and post-market surveillance to ensure continuous device safety throughout its lifecycle.
• Communicate Across Teams: Effective communication is paramount. Technical biocompatibility information must be translated for different teams—from regulatory and quality to marketing and sales—by highlighting the impact on deadlines, compliance, and patient safety.

References

• Netflix Documentary, The Bleeding Edge: A documentary that exposes systemic flaws and risks within the medical device industry, featuring the case of the Essure device.
• ISO 10993-1: The international standard for the biological evaluation of medical devices, which is undergoing revisions to emphasize a lifecycle-based approach to safety.
• Etienne Nichols' LinkedIn: For more insights on MedTech and quality management, connect with Etienne at https://www.linkedin.com/in/etienne-nichols.

MedTech 101: Extractables & Leachables

In simple terms, extractables are all the potential chemicals that could leak out of a medical device under harsh lab conditions, like high temperatures or strong solvents. Think of it as a comprehensive stress test to find every single chemical component.

Leachables, on the other hand, are the chemicals that actually leak out under normal, clinically relevant conditions. This is what a patient's body might be exposed to during the device's actual use.

Regulatory bodies like the FDA often require both types of analysis to ensure a comprehensive understanding of a device's chemical profile.

Feedback Call-to-Action

Have thoughts on today's episode or a topic you'd like us to cover? Your feedback is invaluable. Email your comments and suggestions directly to us at podcast@greenlight.guru. We read and respond to every email.

Sponsors

This episode is brought to you by Greenlight Guru, the only medical device success platform designed specifically for MedTech companies. Their all-in-one platform includes both a QMS and a Clinical Data Management System (EDC), providing a single source of truth for all your product development and clinical data. By streamlining your processes, Greenlight Guru helps you get safer, higher-quality medical devices to market faster and with less risk.

Greenlight Guru's platform aligns perfectly with today's discussion on integrating biocompatibility into the QMS. By providing a centralized, risk-based system, it helps teams proactively manage design controls and post-market surveillance, ensuring biological safety is considered throughout the entire device lifecycle. To learn more, visit www.greenlight.guru.

They challenge the common "wait until something breaks" approach, emphasizing that the most effective MedTech teams integrate an EQMS early in the product lifecycle. The conversation covers the strategic and financial benefits of a well-implemented EQMS, the key stakeholders who should be involved in the evaluation process, and the core criteria for selecting the right software.

Rogantino highlights the importance of a purpose-built system and shares actionable advice on turning a quality system investment into a powerful tool for collaboration, efficiency, and audit readiness.

Key Timestamps

• 03:13 When is the right time to evaluate an EQMS?
• 04:27 How to prioritize an EQMS investment.
• 05:15 The three pillars of a MedTech company: financial, ethical, and legal/regulatory.
• 07:28 The dual benefits of an EQMS: reducing risk and increasing efficiency.
• 11:59 Who should be involved in the evaluation process?
• 17:32 What to look for when evaluating an EQMS.
• 23:13 The importance of a user-friendly interface.
• 26:53 Navigating the sales and demo process.
• 28:49 Defining clear success criteria for a QMS partnership.
• 31:45 What to avoid during the evaluation and purchasing process.
• 36:52 The compounding risk of doing nothing.
• 40:23 The importance of clinical data and its connection to the QMS.

Quotes

• "When your house is already on fire, it's a little late to install some sprinklers." — Andy Rogantino.
• "If you're asking the question, 'should we build a QMS?', you probably should." — Etienne Nichols.

Takeaways

1. Prioritize Quality Early: Delaying an EQMS evaluation until a regulatory event or product issue occurs puts a company at a significant disadvantage. The most successful MedTech teams treat their QMS as the foundation of their business from the earliest stages of development.
2. Include All Stakeholders: An EQMS is not just for the quality department. Involve product development, regulatory, IT, and leadership. A system that breaks down silos and promotes collaboration across the entire organization is key to long-term success.
3. Invest for ROI: An EQMS is an investment, not an expense. It should be evaluated based on its potential to positively impact the financial bottom line by streamlining processes, reducing the risk of recalls or 483s, and accelerating time to market.
4. Seek a Purpose-Built Solution: Avoid generic, overly-customizable QMS platforms. A system built specifically for the MedTech industry, like Greenlight Guru, provides built-in guardrails and best practices that ensure compliance with standards like ISO 13485 and 21 CFR Part 820 from day one.
5. Evaluate for User Experience: The best software is simple and intuitive. During the evaluation process, consider how the system will feel for the people using it daily. A poor user interface can lead to low adoption and workarounds, negating the benefits of the investment.

References

• Cardiac Arrest: Five Years as a CEO on the Feds’ Hit List by Howard Root: A recommended read for MedTech leaders on the importance of robust quality systems and regulatory compliance.
• 21 CFR Part 820, ISO 13485, ISO 14971, and ISO 9001: Key regulatory and quality standards that an effective MedTech EQMS should be built to handle.
• Etienne Nichols’ LinkedIn: linkedin.com/in/etiennenichols
• Andy Rogantino’s LinkedIn: linkedin.com/in/andyrogantino

MedTech 101

• EQMS (Electronic Quality Management System): An electronic system for managing quality processes and documents in a regulated industry. In MedTech, this software helps companies comply with standards like ISO 13485 and FDA regulations by managing design controls, risk, document control, and other quality-related activities.

Audience Engagement

Poll Question:

• When does your company typically start thinking about a QMS?
• A. Before development even begins.
• B. During the design and prototyping phase.
• C. When we're preparing for our first regulatory submission.
• D. When we receive a regulatory finding or warning letter.

Feedback Call-to-Action

Have thoughts on today's episode or want to suggest a future topic? We want to hear from you. Email us at podcast@greenlight.guru. Your feedback helps us deliver the most relevant and actionable content to the MedTech community.

Sponsors

• Greenlight Guru: The leading purpose-built Electronic Quality Management System (EQMS) for medical device companies. Greenlight Guru's platform is designed to help MedTech innovators bring safer, more effective products to market faster, ensuring compliance and efficiency from day one. To learn more, visit www.greenlight.guru.

They delve into the nuances of software changes, design creep, and off-label marketing, providing a critical look at how companies can avoid common pitfalls.

This discussion is vital for MedTech professionals seeking to understand the true nature of FDA expectations and build more robust quality systems.

Timestamps

• 00:04 – Introduction to common FDA compliance issues
• 02:02 – Discussion on FDA's policy of not naming individuals
• 05:45 – Mike Drues challenges the "pre-market" classification of common issues
• 09:20 – Documentation requirements for different device classes
• 11:35 – Mike’s take on the most common FDA issues (beyond the presented three)
• 15:40 – Root causes of common compliance problems and industry responsibility
• 20:00 – The role of regulation and FDA's responsibility in clarity
• 27:05 – Deep dive into design change and design creep
• 31:40 – Software changes and the "bug fix" mentality
• 35:45 – Marketing beyond authorized intended use with a real-world example
• 41:00 – Key takeaways and proactive compliance strategies

Standout Quotes

• "If the regulation makes sense, we shouldn't need it. If the regulation doesn't make sense, we shouldn't have it." — Mike Drues. This quote encapsulates Mike's philosophy on regulatory compliance, emphasizing that true professionalism means understanding inherent needs rather than just following rules.
• "You have a piece of software, you have a bug, you fix the bug… Is your job done? Absolutely not." — Mike Drues. This highlights a critical oversight in software development within MedTech, stressing the importance of holistic post-fix validation to prevent unintended consequences.

Top Takeaways

• Regulatory Misclassification: Many issues labeled by the FDA as "pre-market" (e.g., marketing beyond intended use, design creep) are fundamentally post-market compliance challenges. This distinction is crucial for companies to allocate resources effectively.
• Beyond Administrative Review: While administrative incompleteness accounts for a significant portion of 510(k) rejections (around 38%), the scientific and substantial equivalence reviews are major hurdles, with approximately 75% of 510(k)s rejected initially, primarily due to lack of substantial equivalence (85% of those rejections).
• Top Post-Market Violations: Historically, the most common reasons for FDA 483s and Warning Letters relate to CAPAs (12.5%), design controls (12.5%), and complaint handling (10.5%), collectively accounting for roughly 35% of all post-market issues. Companies should prioritize these areas.
• Software Change Management: Fixing a software bug is only the first step; a holistic review is essential to ensure no new problems are introduced and the device's safety, efficacy, and usability remain uncompromised.
• Intentionality vs. Compliance: Marketing a device beyond its authorized intended use, even if the device functionally performs beyond its cleared claims, carries significant regulatory and product liability risks. Companies should seek appropriate clearance for expanded claims rather than relying on off-label promotion.

References & Links

• Etienne Nichols' LinkedIn
• Greenlight Guru

Call to Action

Greenlight Guru is purpose-built for MedTech. See how it can transform your quality system with a personalized walkthrough — get your demo here.

They discuss the expansive definition of neurotech, the significant challenges in accelerating innovation—particularly concerning regulatory frameworks and cross-functional collaboration—and how a united industry voice can overcome these hurdles to bring life-changing devices to patients faster.

Timestamps

• 00:04 - Introduction to the episode and Matt Stratton
• 02:21 - Matt Stratton’s journey into neurotechnology and passion for acceleration
• 04:30 - Defining neurotech beyond traditional boundaries
• 07:11 - Major challenges preventing acceleration in neurotech
• 10:16 - The internal and external barriers to collaboration
• 13:40 - The "generalist vs. specialist" dilemma in neurotech expertise
• 17:03 - Optimizing existing neurotech and the future of advanced neuroscience
• 19:34 - What neurotech can learn from other medical device verticals
• 22:50 - The complexity of the brain: "What is normal?"
• 24:50 - Ethical considerations of neurotech advancements
• 26:27 - Overcoming competitive intelligence in collaborative communities
• 29:05 - Bridging the language gap between pharma and medical devices in neurotech
• 31:40 - Matt Stratton's call to action for the neurotech community
• 33:10 - Political challenges and maintaining focus on shared goals

Standout Quotes

• "I think the neurotech space is a bit broader than that because there are so many interrelated areas that are relying and using very similar technologies and ultimately aiming for the same patient groups...and will come across the same regulatory structures." — Matt Stratton
• Matt's expansive view highlights the interconnectedness of neurotech, emphasizing that a holistic approach to defining the field is crucial for effective collaboration and regulatory navigation.
• "If what ties us together is greater than the soil we stand on, then yeah, we can remain standing together." — Etienne Nichols
• Etienne's profound statement underscores the power of shared purpose and patient-centric goals in transcending political and competitive barriers within the medical device industry.

Top Takeaways

• Broadening the Neurotech Definition: Neurotech extends beyond neuromodulation and BCIs to include neurodiagnostics, neuromonitoring, neurological drug delivery, and neurosurgical devices. This broader perspective fosters greater collaboration and addresses common regulatory and patient needs.
• Challenges in Acceleration: Key hurdles include complex regulatory environments, the need for increased collaboration among diverse experts (neuroscientists, biologists, engineers), and adapting to emerging technologies like AI.
• The Power of External Collaboration: Bringing together different industry players helps establish a unified voice for regulatory changes, benchmark best practices, and break down barriers to faster progress, especially as neurotech pushes ethical and technological boundaries.
• Learning from Other Verticals: While neurotech faces unique challenges, insights from established fields like orthopedics and CRM, particularly regarding rapid product development (e.g., "Moore's Law" in tech), offer valuable lessons for accelerating innovation.
• Navigating Complexity and Ethics: The brain's inherent complexity and the fluid concept of "normalcy" introduce unique challenges for neurotech. This includes addressing profound ethical considerations, such as the potential for enhanced human capabilities to exacerbate societal inequalities.
• Fostering Open Dialogue: Community platforms that focus on "mundane" structural and regulatory challenges—rather than confidential IP—can successfully foster collaboration among competitors, demonstrating that shared non-competitive problems are abundant and fruitful for discussion.

References & Links

• Matt Stratton LinkedIn
• Etienne Nichols LinkedIn
• Coalition

Call to Action

Greenlight Guru is purpose-built for MedTech. See how it can transform your quality system with a personalized walkthrough — get your demo here.

They discuss the launch of the GCSA certification and IAOCR accreditation now available in the Americas, exploring how these standards improve site credibility, de-risk clinical trials, and offer faster pathways for medtech market access. From regulatory advantages to site selection strategies, this episode is essential listening for sponsors, CROs, and MedTech leaders navigating global trials.

Key Timestamps

00:02 – Introduction to Julio Martinez-Clark and episode overview

02:10 – What is GCSA and IAOCR certification?

06:00 – Why certification is emerging now: volume, complexity, and patient safety

09:42 – Certification structure: site vs. individual requirements

13:45 – The Colombian model: First mover in Latin America

17:55 – Global harmonization vs. local certification pitfalls

21:30 – Measuring ROI of certified vs. non-certified sites

26:15 – Future of global site certification and Latin America’s role

30:00 – Regional differences: speed vs. patient pool in trial site selection

36:15 – Final thoughts on FDA trends and LATAM’s emerging position

Quotes

“It’s appalling that in an industry that deals with lives, there was no global standard to certify site or individual competency—until now.”

– Julio Martinez-Clark

Why it matters: This underscores the critical gap in clinical research infrastructure and the urgent need for standards like GCSA.

“You can’t measure quality without a shared framework. Certification levels the playing field globally.”

– Julio Martinez-Clark

Why it matters: This highlights how global certification allows consistent benchmarking across clinical sites, benefitting sponsors and patients alike.

Key Takeaways

1. GCSA Certification Elevates Site Credibility: Clinical sites with GCSA certification are fast-tracked for sponsor consideration, leading to better trial access and more robust patient recruitment.
2. IAOCR Accreditation Validates Individual Competency: For investigators, coordinators, and site managers, individual accreditation under the UNESCO-backed IAOCR framework offers a portable, verifiable skillset.
3. Latin America Offers Dual Advantages: With rapid recruitment and cost-effective data generation, LATAM is uniquely positioned to lead in globally certified trials—especially Colombia, which already mandates certification.
4. Global Harmonization is Critical: Fragmented local certifications can deter sponsors. A unified global framework like GCSA simplifies compliance, increases efficiency, and builds trust.
5. The FDA Bottleneck May Shift Market Entry: With regulatory delays in the U.S., more medtech firms may turn to Latin America for first-in-human trials and initial commercialization.

References

• Julio Martinez-Clark on LinkedIn
• Bioaccess LATAM
• IAOCR – International Accreditation Organization for Clinical Research
• Etienne Nichols on LinkedIn

MedTech 101: What Is GCSA Certification?

Analogy: Think of GCSA like ISO 9001, but for clinical research sites. It standardizes operational quality and ensures consistent patient safety practices across global locations.

Beginner Example: If a sponsor is choosing between two hospitals, and one has a GCSA badge—it’s like choosing a restaurant with a food safety grade. It builds immediate trust.

Poll Question:

What’s your biggest challenge when selecting global clinical trial sites?

• Assessing quality
• Regulatory alignment
• Patient recruitment speed
• Cost
• All of the above

Engagement Prompt:

Have you worked with certified sites or accredited professionals in your clinical trials? Share your experiences or questions with us at podcast@greenlight.guru.

Feedback

Enjoying the Global Medical Device Podcast? Let us know what topics you want to hear next or leave us a review on your podcast platform of choice. We love your feedback—email us at podcast@greenlight.guru for a personalized reply.

Sponsor Message

This episode is brought to you by Greenlight Guru, the only MedTech Lifecycle Excellence Platform designed to accelerate product development and ensure clinical compliance. Learn more at www.greenlight.guru.

Whether you’re a startup founder, a regulatory lead, or a project manager, this episode offers a sharp lens into the financial planning realities that can make or break product development and commercialization in MedTech.

Key Timestamps

02:34 – Why QMS, regulatory, and clinical are budget afterthoughts for startups

06:45 – What separates experienced vs. inexperienced MedTech founders in budgeting

10:20 – Why software and compliance tools get left out of early budgets

14:12 – How missing budget detail impacts product quality and time-to-market

19:04 – Red flags investors look for in MedTech startup budgets

23:30 – How to improve budgeting accuracy without a CFO

28:10 – Critical cost categories MedTech founders often overlook

35:55 – Advice for recovering from a budgeting oversight

39:40 – Comprehensive checklist of overlooked line items (manual translation, UDI, ISO licenses, and more)

45:00 – Final advice: why networking trumps isolation for smarter budgeting

Standout Quotes

"Relying on the status quo is never good. There are always ways to do things better."

Jon reminds founders and compliance professionals alike that innovation doesn’t stop at the product level—it also applies to budgeting, systems, and team empowerment.

"Getting a 510(k) through is just the starting point. Budgeting like everything ends there is a massive red flag."

This quote highlights the investor’s perspective on sustainability and long-term thinking—crucial traits in any fundable founder.

Key Takeaways

1. Broad Budget Buckets Signal Inexperience

Lumping all compliance-related costs under one line item may look tidy but signals to investors a lack of operational depth. Break out line items for QMS, clinical, regulatory, and software tools.

1. Software and Tools Are Not Optional Extras

Founders must factor in essential systems—like eQMS, CAD, risk management, and clinical data tools—early in budgeting. Assuming a single hire covers everything is a critical mistake.

1. Budgets Must Reflect Time and Scale Realistically

Flat budgets over 2–3 years, or those that assume regulatory costs end at market clearance, raise red flags. Investors expect dynamic budgeting that reflects the realities of growth, post-market surveillance, and team evolution.

1. Outsourcing ≠ All-Inclusive

Many startups underestimate the actual costs tied to consultants and CROs, assuming “someone else is handling it.” Always clarify what’s included—and what’s not.

1. Recovery Is Possible—If You Own It

If your budget’s off-track, clear communication with your board and investors, a willingness to revise, and a plan for worst-case scenarios are your best tools for regaining credibility.

References

• Jon Bergsteinsson on LinkedIn
• Etienne Nichols on LinkedIn
• Greenlight Guru – QMS and Clinical platform for MedTech companies

MedTech 101

Why “One Line for Compliance” Doesn’t Cut It

Think of compliance like building a house. You wouldn’t budget for the entire construction under “tools and materials”—you’d break it out by framing, plumbing, electrical, permits, inspections, and more. In MedTech, the “compliance house” includes QMS platforms, regulatory consulting, ISO standard licenses, clinical software, and ongoing post-market surveillance costs. Each of these is a critical structural element—and each has its own cost profile.

Poll Question:

What budgeting category do you think is most overlooked in early-stage MedTech startups?

• Clinical trial costs
• Regulatory software/tools
• Consultant scope and fees
• Post-market surveillance

Have you ever discovered a major budget blind spot after launching your MedTech project? Tell us what you missed and what you learned—email us at podcast@greenlight.guru. We might feature your story in a future episode.

Feedback

Enjoying the podcast? We want to hear from you! Share your thoughts, leave a review, or suggest a topic you’d love to hear about next. Reach out at podcast@greenlight.guru for a personalized response from our team.

Sponsors

This episode is brought to you by Greenlight Guru, the MedTech lifecycle platform trusted by medical device companies worldwide. Whether you're budgeting for your first study or scaling to new markets, Greenlight Guru Quality and Clinical helps you move faster while proving safety and effectiveness. Learn more at greenlight.guru.

Ashkon shares a phased approach to aligning QMS implementation with product development, explains the concept of "enforcement points," and reveals how founders can reduce the burden of compliance by starting small and planning ahead. If you're navigating regulatory requirements while trying to stay innovative, this episode is your roadmap to smarter, leaner quality.

Key Timestamps

• 00:02 – Introduction to Greenlight Guru and medtech process integration
• 01:15 – QMS evolution from startup to commercialization
• 03:00 – Phase-based product development overview (Phases 0–6)
• 06:35 – Why QMS should follow product needs, not just regulatory triggers
• 09:10 – Agile vs. proceduralism in quality systems
• 11:50 – Building a quality culture during the feasibility phase
• 15:25 – When to implement QMS controls and how to prepare for “enforcement points”
• 18:40 – Investor-driven and regulatory QMS triggers
• 21:10 – How early QMS planning saves time and reduces future remediation
• 26:20 – Ashkon’s final advice for startups: start small and stay proactive

Standout Quotes

"You’ve got to take the BS—being burdensome—out of QMS."

Ashkon Rasooli redefines QMS as a project management tool, challenging the notion that compliance must be a burden. This quote encapsulates his philosophy of proactive, phased implementation that actually enhances product development.

"Start small and do a little bit at a time—it won’t seem like a burden."

A practical mantra for startups, this advice underscores how a gradual, well-aligned QMS rollout can prevent last-minute fire drills and wasted effort.

Top Takeaways

1. Use the "Phase 0–6" Model to Guide QMS Rollout – Align QMS implementation with the stages of product development to ensure each step supports the next.
2. Don’t Wait for Enforcement Points – Start building your QMS before regulators or investors demand it to avoid remediation-heavy implementations.
3. Prioritize Culture Before Controls – In early feasibility, focus on aligning your team with medtech’s safety responsibilities, rather than formal procedures.
4. Procedures Should Support Outcomes, Not Just Check Boxes – Avoid proceduralism by tying every process back to its intended quality objective.
5. Regulatory Strategy = Investor Strategy – QMS maturity is increasingly scrutinized during due diligence. Treat it as a value driver, not just a cost.

References

• Ashkon Rasooli on LinkedIn
• Greenlight Guru – Quality management software for medical devices
• Etienne Nichols on LinkedIn – Connect with the host
• ISO 13485 vs. ISO 9001 – Explains how medical device quality systems build on general standards
• ISO 14155 Overview – Relevant for clinical validation procedures

MedTech 101: What Are “Enforcement Points”?

In the context of QMS, enforcement points are moments when external stakeholders (regulators or investors) require proof of formalized processes. Think of it like a driver’s license checkpoint—you may be cruising just fine, but at that moment, you must prove you’re compliant. The earlier you prep for them, the smoother your journey.

Poll Question:

Where is your company on the QMS journey?

A) Pre-feasibility (Phase 0)

B) Early product planning (Phase 1–2)

C) Preparing for launch (Phase 4–5)

D) Post-market and scaling (Phase 6+)

E) Not sure where we stand

What’s one thing you wish you knew earlier about building your QMS? Share your thoughts at podcast@greenlight.guru.

Feedback CTA

Enjoying the Global Medical Device Podcast? Help us shape future episodes—leave a review on your favorite platform or email us at podcast@greenlight.guru. We read every message and respond personally!

Sponsor Integration

This episode is powered by Greenlight Guru, the only quality management software designed specifically for medtech. Whether you're defining your quality policy in Phase 1 or preparing for design transfer in Phase 5, Greenlight Guru helps you stay aligned, compliant, and agile.

From navigating state-specific registration, sales tax laws, and distribution logistics to choosing between direct and distributor-based strategies, Adam shares hard-earned insights for avoiding the "second valley of death" post-clearance. Whether you're a domestic startup or an international company entering the U.S., this episode arms you with a tactical understanding of compliance landmines and scalable go-to-market strategies.

Key Timestamps

• 00:02 – Intro: The real MedTech “valley of death” after FDA clearance
• 04:45 – Why U.S. state-level registration is misunderstood and overlooked
• 08:15 – State-level definitions of medical devices and why they differ
• 11:20 – Strategic go-to-market options: Distribution vs. Direct
• 17:00 – How regulations vary drastically by state (CA, TX, etc.)
• 21:50 – The real risks of noncompliance: lawsuits, bad PR, and due diligence failures
• 26:15 – Why distribution agreements can stall your growth (and how to avoid it)
• 34:30 – Sales tax & use tax: The hidden compliance trap
• 39:10 – Logistics, warehousing, and long-term liabilities in contracts
• 44:55 – Overlooked pitfalls: Secretary of State filings and income tax in 36+ states
• 51:15 – Software as a Medical Device (SaMD): U.S. compliance still applies
• 55:30 – Selling to the U.S. government vs. private sector buyers
• 59:20 – Veterinary devices and why they still need regulatory controls
• 1:03:10 – What a winning go-to-market strategy actually looks like
• 1:10:25 – Adam’s final advice to MedTech startups (foreign and domestic)

Standout Quotes

"You're not entering one country—you're entering 50 states and D.C. Each with its own rules, definitions, and tax laws."

—Adam Steadman explains why U.S. MedTech entry requires a state-by-state strategy, especially for international companies.

"None of the strategics want your warehouse management system—they want your product, your sales, and your proof of market fit."

—Steadman on why building non-core infrastructure slows down commercialization and valuation.

Top 5 Takeaways

1. FDA Clearance ≠ Market Readiness – State-level registrations, sales tax laws, and pharmacy board definitions often delay or block commercialization.
2. Distribution Isn’t Always a Shortcut – National distributors may have misaligned incentives and can lock you into exclusivity that hinders growth.
3. Sales Tax is a Regulatory Minefield – 46 states require separate sales tax registration, exemptions tracking, and monthly filings—even if you're tax-exempt.
4. Beware of Long-Term Contracts – Logistics and distribution contracts often lock companies into rigid terms that prevent pivots or acquisitions.
5. Speed to Market Is Strategic – Getting to market fast is often the difference between becoming #1 or #3—and #3 often gets nothing.

MedTech 101

What Is “Nexus” and Why It Matters for Sales Tax?

“Nexus” refers to the minimum level of economic activity that triggers tax obligations in a given state. For example, selling $100,000 of devices or 200 transactions may establish nexus, requiring you to register for sales tax. Unlike VAT in Europe, U.S. sales tax laws are state-specific, making this a major compliance hurdle for MedTech companies.

References & Resources

• Adam Steadman on LinkedIn
• Etienne Nichols on LinkedIn
• MDD Options – Adam’s Company
• Greenlight Guru Quality Platform

Poll Question:

Which part of U.S. market entry do you feel least prepared for?

• State-level licensing
• Sales tax registration
• Distribution strategy
• Logistics & warehousing
• All of the above

Have you faced unexpected delays due to state-level regulations? Share your story—we may feature it in a future episode.

Feedback & Contact

Enjoying the podcast or have ideas for future topics? We’d love to hear from you!

Send your thoughts to podcast@greenlight.guru – we read every message and often reply personally!

Sponsor Message

This episode is brought to you by Greenlight Guru Quality – a purpose-built QMS platform that keeps you always audit-ready. Organize evidence by requirement, flag gaps, and avoid the scramble before inspections. Don’t get ready—stay ready.

Mike challenges MedTech professionals to rethink how we engage with the system, exposing how widespread underreporting and data hygiene problems not only weaken safety efforts but also increase legal risk. This eye-opening discussion reveals where the breakdowns are occurring, who’s responsible, and what industry and regulators can do to fix it.

Key Timestamps

• [02:30] What is the MAUDE database, and why does it matter?
• [06:10] The critical difference between reportable and non-reportable adverse events
• [11:20] Limitations of MAUDE: Why FDA warns against using it for rate comparisons
• [17:45] Underreporting, late submissions, and missing data: The disturbing stats
• [25:00] High-profile companies dominating late reporting violations
• [32:10] Legal consequences: What expert witnesses look for in MAUDE data
• [38:50] Is it poor systems or lack of regulatory understanding causing failures?
• [46:00] Recommendations for manufacturers: What responsible reporting looks like
• [53:20] How FDA could modernize the MAUDE database to better serve patients
• [1:01:30] Carrots or sticks: Creating incentives vs. penalties for compliance
• [1:09:00] Final thoughts: The true mission of MAUDE and how to fulfill it

Standout Quotes

"A report in the MAUDE database is just a historical record. It doesn’t say why it happened or who’s at fault—just that it happened."

— Mike Drues

This quote underscores the limited utility of MAUDE reports and why interpretation requires caution.

"If you're not a medical device professional without your tools, then you're not really a medical device professional."

— Etienne Nichols

A poignant reminder that compliance and quality are human-led, not software-enabled by default.

Top Takeaways

Late Reporting is Widespread and Risky

• Nearly 30% of MAUDE reports are filed late, with 10% submitted more than six months past due. This creates legal exposure and potential patient harm.

MAUDE Is Misused—Despite FDA Warnings

• Manufacturers commonly use MAUDE for competitive analysis or trend detection, even though the FDA explicitly warns against it.

Three Companies Account for Over Half of Late Reports

• Large, well-resourced companies like Medtronic and Becton Dickinson are responsible for a disproportionate share of noncompliance.

Electronic Tools Help, but Culture Matters More

• Software can support MDR timelines, but organizations still need internal processes and urgency to act responsibly.

FDA and Industry Both Need to Evolve

• Suggestions include AI-driven cross-referencing, tiered reporting urgency, and incentive-based compliance recognition.

References

• FDA MAUDE Database
• 21 CFR 803.16 – MDR Reporting Requirements
• Etienne Nichols on LinkedIn

MedTech 101: What Is MAUDE and Why Should You Care?

Think of the MAUDE database as a public logbook of adverse events involving medical devices in the U.S. Unlike peer-reviewed literature or formal recalls, MAUDE captures both mandatory and voluntary reports—from manufacturers, healthcare professionals, and even patients. However, it's not a perfect dataset. Think of it like Yelp for medical device failures: informative, but filled with inconsistencies, duplicates, and vague reviews.

Poll Question:

How confident are you in your organization’s ability to report adverse events to the FDA on time and accurately?

Have you ever tried to use the MAUDE database for competitive analysis or submission support? Share your experience—was the data helpful, misleading, or incomplete?

Feedback

Have a topic suggestion or feedback on today’s episode? We want to hear from you. Email us at podcast@greenlight.guru and get a personal response from our team.

Sponsors

Today’s episode is brought to you by Greenlight Guru, the only MedTech-specific QMS software that empowers companies to simplify complaint handling, streamline MDR submissions, and improve audit readiness. If you're ready to evolve beyond spreadsheets and silos, visit greenlight.guru.

With real-world analogies, like orchestras and dashboards, Muzio explains how leaders can create alignment, drive faster decisions, and unlock collaborative problem-solving by focusing on the future instead of the past. Whether you're part of a startup or an established MedTech firm, this episode delivers actionable strategies to help your team iterate with purpose.

Key Timestamps

• [00:01] Introduction and sponsor message from Greenlight Guru
• [01:13] Meet Ed Muzio and the premise of Iterate
• [03:15] Why most management meetings don’t drive real action
• [06:40] The “Alice” video case study and how it exemplifies iterative management
• [11:50] Common objections and barriers to implementing iterative processes
• [17:00] Using forward-looking data instead of status updates
• [22:08] MedTech example: anticipating 510(k) review delays
• [29:15] Making decisions early to gain planning time
• [34:20] How to get started if you’re a small or early-stage company
• [37:40] Cultural barriers in iterative team models
• [41:20] Handling matrixed environments and CEO-level priorities
• [47:10] Why clarity of decision-makers matters in early teams
• [51:45] The biggest mistake mature companies make in team meetings
• [55:05] Final advice: focus on behavior, not buzzwords

Standout Quotes

“If you walk into a meeting and it's 26 minutes in and you haven’t made a decision yet—and that’s normal—you’re probably not solving anything.”

—Ed Muzio on the inefficiency of status-only meetings in traditional management culture.

“We don’t need to forecast history. We need to plan around the future.”

—Ed Muzio explaining why forward-looking metrics are the only actionable data in iterative teams.

These quotes challenge conventional meeting norms and emphasize a proactive mindset crucial to success in fast-moving MedTech environments.

Top Takeaways

1. Backward-looking metrics kill momentum. Most leadership teams spend meetings reviewing past progress. Instead, focus on forecasting future outcomes and addressing variances before they become problems.
2. Accountability must be systemic, not personal. A team can only normalize issue-raising if the entire culture shifts to expect it—making it safe and standard to surface concerns early.
3. “Succeed or fail together” breaks silos. When departments align to shared goals, cross-functional collaboration becomes natural. Incentives that isolate progress undermine execution speed.
4. Don’t vote—decide. In small teams, designate a clear decision-maker and avoid democratic processes that lead to politicking instead of clarity.
5. Adopt flexible systems over rigid charts. Org charts don’t reflect reality. Iterative management embraces the messiness of matrixed teams and adapts meetings and collaboration structures fluidly.

References

• Iterate by Ed Muzio – Book on accelerating team alignment and decision-making
• IterateNow.com – Access free videos and practical management tools from Ed Muzio
• Etienne Nichols on LinkedIn – Connect with the podcast host

MedTech 101: What Is Iterative Management?

Iterative management is like adjusting your GPS route in real time—rather than simply reviewing where you’ve been, you keep making small course corrections to reach the goal faster. In a MedTech context, this means shifting focus from milestone recaps to real-time issue resolution, involving all departments in forward-looking planning. Visual tools like pragmatic dashboards (with projected vs. actual timelines) help clarify where corrections are needed.

Poll Question:

What’s the biggest obstacle your team faces in solving problems before they escalate?

• Status-focused meetings
• Lack of cross-functional alignment
• Fear of raising issues
• Unclear decision-making authority

Engagement Prompt:

Have you ever worked in a team where raising early concerns was encouraged—not penalized? Share your experience and tag a team leader who made it work.

Feedback & Listener CTA

Enjoying the podcast? We'd love to hear your feedback. Email us at podcast@greenlight.guru with your thoughts, questions, or suggestions for future guests. Every email gets a personal response!

Sponsors

This episode is brought to you by Greenlight Guru—the only quality management system built specifically for MedTech. Want your design history file audit-ready and effortlessly connected across departments? Learn more at www.greenlight.guru.

From costly engineering missteps like ignoring tolerance stack-ups to the human factors issues that derail usability in the OR, Justin shares battle-tested advice based on his experience reviewing hundreds of device designs. He also delivers a wake-up call to startups overly focused on licensing or acquisition as the endgame. Whether you're an engineer, founder, or CEO, this episode offers critical insights into how to build a product that works—and a company that lasts.

Key Timestamps

• 00:00 – Introduction & Greenlight Guru Sponsor Message
• 01:26 – Live from LSI: Introducing Justin Bushko
• 02:55 – Why Early-Stage Engineering Mistakes Derail Companies
• 04:12 – The Critical Role of DFM and Tolerance Analysis
• 06:20 – Real-World Usability Failures: FDA Warning on Cranial Fixation Devices
• 08:10 – Human Factors Oversights & Surgeon Behavior
• 10:25 – What CEOs Should Focus On vs. Engineers
• 12:20 – Economic Buyers, KOLs, and Commercialization Challenges
• 14:05 – Don’t Chase the Exit: Why Founders Should Build for Longevity
• 16:00 – Final Thoughts and Takeaways

Standout Quotes

“If your partners can’t explain how and why they did your tolerance analysis, they probably didn’t do it right—and it’ll cost you nine months later.”

—Justin Bushko, on the hidden dangers of relying too heavily on outsourced design partners.

“Founders aiming for a quick exit send the wrong message. Build something sustainable. Acquisition should be a byproduct—not the goal.”

—Justin Bushko, challenging the exit-first mindset common in early-stage MedTech.

Top Takeaways

1. DFM & Tolerance Analysis Are Non-Negotiable: Skipping detailed design-for-manufacturing and tolerance stack analysis often leads to failure right before tooling and commercialization—when funds are already tight.
2. Human Factors Must Be Built-In Early: Surgeons may not use your product as intended. Validate with a wide range of KOLs to uncover unintended use or misuse.
3. Test for High-Risk Use Cases Early: For devices like inserters, test mechanical thresholds that could lead to field failures. Don’t wait until post-market feedback.
4. Understand Economic Buyers, Not Just KOLs: A surgeon’s support doesn’t guarantee adoption. You need champions who can advocate to hospital boards and procurement teams.
5. Stop Chasing Exits—Build Real Companies: Investors and acquirers see through the “quick flip” mentality. A sustainable business model attracts more serious interest.

References

• Greenlight Guru – Sponsor and end-to-end MedTech quality management platform
• Justin Bushko on LinkedIn
• Etienne Nichols on LinkedIn
• Medical Device Fireside Chats – Justin Bushko’s Book (Amazon) (If mentioned/linked on-site)

MedTech 101: What is Tolerance Stack-Up Analysis?

Imagine building a puzzle where each piece is just slightly off in size—by the time you put it all together, nothing fits. That’s what tolerance stack-up is about. Every part in a device has a manufacturing variation. If those tolerances aren’t analyzed cumulatively, you can end up with a product that doesn’t assemble or fails under stress. Tolerance analysis helps predict and prevent these compounding errors before they happen.

Poll Question:

What’s the biggest product development risk in early-stage MedTech?

• Tolerance stack-up issues
• Ignoring human factors
• Economic misalignment with buyers
• Rushing to an early exit

Discussion Prompt:

Have you ever seen a product fail in the field due to a design assumption? Share your story and how it changed your approach.

Feedback

Enjoyed the episode? Want to hear more from product engineers, founders, or regulators? Let us know!

Send your feedback, guest ideas, or questions to podcast@greenlight.guru — we read every email and respond personally.

Sponsor Mention

This episode is brought to you by Greenlight Guru, the only MedTech-specific quality management platform. Whether you’re an engineer working through DFM or a CEO planning your go-to-market strategy, Greenlight Guru helps you manage compliance, risk, and innovation—all in one place.

Whether you're a quality professional trying to build compliant systems or an innovator racing toward FDA submission, this episode lays out exactly what you need to know to stay ahead of cyber threats and within regulatory guardrails.

Key Timestamps:

• 00:01 – Intro to guest Christian Espinosa and Blue Goat Cyber
• 06:28 – Why medical device cybersecurity is different from traditional IT security
• 11:49 – Real-world hacking example: acne laser device turned skin-burner
• 13:57 – FDA expectations post-September 2023: what changed
• 17:12 – Secure boot: a microcontroller mistake that derailed a launch
• 20:35 – Common cybersecurity vendor mistake MedTech companies make
• 23:40 – SBOM: Software Bill of Materials and why it's legally critical
• 27:58 – Cyberattacks in hospitals: assuming a hostile network
• 35:44 – AI in medical devices: data bias and cybersecurity challenges
• 41:10 – Developers ≠ cybersecurity experts: the training gap nobody talks about
• 45:20 – What RA/QA professionals need to know now
• 49:30 – Why cybersecurity must be iterative, not a final-phase add-on
• 55:20 – Espinosa's final advice for MedTech professionals
• 57:52 – The story behind “Blue Goat Cyber”

Standout Quotes:

“Cybersecurity for medical devices isn’t about data breaches—it’s about patient harm. You could paralyze someone or misdiagnose sepsis. This isn’t theoretical.”

— Christian Espinosa, on the real risks of insecure devices

“Most developers don’t understand cybersecurity. We assume they do—but that’s like expecting an architect to be a locksmith.”

— Christian Espinosa, on why so many devices fail security assessments

Top Takeaways:

1. Cybersecurity isn’t just about data—it's about patient safety. From burning skin to missed sepsis diagnoses, vulnerabilities in devices have real-world harm potential.
2. FDA now requires more than just a basic security plan. Post-September 2023 rules mandate testing (SAST, DAST, fuzzing), SBOMs, and risk assessments tied to patient harm.
3. Start cybersecurity planning during the requirements phase. Hardware like microcontrollers must support secure boot and other protections—retrofits can cripple product plans.
4. Iterate cybersecurity like any core development activity. One-time testing near submission is too late; build security into your pipeline just like QA or usability.
5. Traditional cybersecurity vendors aren’t enough. Many fail to meet FDA’s nuanced expectations for medical devices, causing costly submission rejections.

References & Resources:

• Christian Espinosa on LinkedIn
• Blue Goat Cyber
• Etienne Nichols on LinkedIn

MedTech 101 – Understanding SBOM (Software Bill of Materials):

Think of an SBOM like a nutrition label on food. Just as you want to know if a product contains allergens or preservatives, FDA wants to know what libraries and components are in your software. A clean, complete SBOM identifies both security vulnerabilities and potential licensing conflicts—like borrowing ingredients you’re not legally allowed to use. Want a visual explanation? Consider a flowchart showing third-party libraries linking into your main software repository, flagged with vulnerability scores.

Poll Question:

Is cybersecurity currently integrated into your product development process—

A) From Day 1

B) Only near submission

C) We outsource and hope for the best

D) What cybersecurity?

What’s your biggest challenge when it comes to building cybersecurity into your product lifecycle? Email us your thoughts at podcast@greenlight.guru.

Feedback:

If this episode sparked new insights or raised questions, we’d love to hear from you. Send us your feedback or suggest a topic at podcast@greenlight.guru. We personally respond to every email and appreciate your ideas for future guests and discussions.

Sponsored by Greenlight Guru:

Most companies spend more time preparing for audits than in the audit itself. Greenlight Guru Quality lets you link cybersecurity and quality evidence directly to requirements, making you “always audit-ready.” Learn more at www.greenlight.guru.

This episode dives deep into what triggers a new submission, how usability testing and human factors play an expanded role for lay users, and the regulatory logic that guides these transitions. The conversation highlights the importance of aligning regulatory strategy with business goals, and offers practical insights on leveraging real-world evidence, understanding the limits of FDA databases, and optimizing pre-submission meetings.

Key Timestamps

• 02:10 – Starting from a cleared 510(k): Do you need a new submission for OTC?
• 06:45 – Implications of removing the healthcare provider from the equation
• 12:00 – Risk management: Expanding risk profiles when lay users are involved
• 18:15 – When a 510(k) becomes a De Novo or PMA
• 22:50 – Usability testing and the risk of user error in OTC devices
• 31:20 – Clinical investigations and good clinical practices (GCPs)
• 36:00 – Real-world evidence vs. real-world data—what’s usable?
• 41:30 – Using Pre-Subs effectively and what “quality data” really means
• 47:10 – Labeling, cleaning, and UDI for OTC products
• 53:40 – OTC software and digital health—when is it a regulated device?
• 01:00:00 – Summary: Aligning regulatory logic with common sense and business strategy

Quotes

“With an OTC device, we are taking the healthcare professional totally, completely, and utterly out of the loop.”

– Mike Drues

This quote encapsulates the core regulatory challenge in moving a device to OTC: every element, from labeling to usability, must assume zero clinical supervision.

“If the clinical trial won’t tell you anything you don’t already know from good real-world evidence, why spend the time and money?”

– Mike Drues

A powerful argument for using well-documented real-world evidence over unnecessary trials—provided the data truly meets evidentiary standards.

Top Takeaways

1. Label Expansion ≠ Shortcut: Moving from prescription to OTC usually requires a new submission—especially when removing the healthcare provider introduces new risks.
2. Usability Testing Is Critical: OTC usability studies must go beyond IFU comprehension to include risk of misuse, poor device selection, and user decision-making.
3. Real-World Evidence Can Help—If It’s Clean: Real-world data isn’t always usable. FDA will expect reproducibility, traceability, and strong justifications.
4. Labeling & Design Must Assume No Clinical Oversight: Cleaning procedures, warnings, and directions must all be validated for home use and layperson comprehension.
5. Use Pre-Subs Wisely: Especially for label expansions or gray-area digital health tools, pre-subs provide critical alignment with FDA and prevent costly errors.

References & Resources

• Etienne Nichols on LinkedIn
• FDA Guidance on Real-World Evidence for Regulatory Decision-Making
• Greenlight Guru Webinar: What is and Isn't a Regulated Medical Device (feat. Mike Drues)
• FDA Guidance: Clinical Decision Support Software

MedTech 101: OTC vs Prescription Devices

Analogy: Think of prescription vs. OTC devices like driving a manual vs. automatic car. Prescription devices assume a trained “driver” (the healthcare provider), while OTC devices must be intuitive and safe enough for anyone to “drive” without instruction.

Graphic Suggestion: A split diagram comparing IFU complexity, user training, and supervision levels between Rx and OTC pathways.

Concept Simplified: Usability testing for OTC devices isn’t just about making it “easy”—it’s about ensuring safety in the absence of clinical guidance.

Audience Engagement

Poll Question:

Have you ever considered transitioning a medical device from prescription to OTC?

• Yes, we’ve explored it
• No, but we’re curious
• We plan to stay prescription-only
• Not applicable to our device

What’s your biggest challenge in designing for lay users? Share your thoughts with us on LinkedIn or email us at podcast@greenlight.guru—we’d love to hear your story.

Feedback Request

Enjoying the Global Medical Device Podcast? Help us improve! Leave a review on your favorite platform, or email us directly at podcast@greenlight.guru with feedback or topic suggestions. We personally read every message and love hearing from you.

Sponsor Note

This episode is brought to you by Greenlight Guru, the only MedTech-specific Quality and Clinical platform. Whether you're transitioning to OTC or optimizing your device's QMS, Greenlight Guru is your partner for faster development and safer products. Visit www.greenlight.guru to learn more.

This episode unpacks how intended users, environments, and risk tolerances shape device categorization, and why usability testing is far more complex than many realize. Whether you're developing a consumer health product or preparing a label expansion strategy, this is a must-listen for your regulatory roadmap.

Key Timestamps

• [03:05] – What defines an OTC vs. prescription medical device?
• [06:45] – Market size of OTC devices and major product categories
• 10:00 – Label expansion: moving from Rx to OTC status
• 13:22 – The role of intended use environment in OTC classifications
• 20:40 – Examples of devices in each FDA class that are OTC
• 26:30 – Prescription devices used in home settings vs. true OTC
• 31:15 – Characteristics that qualify devices for OTC status
• 37:55 – Self-diagnosis, self-selection, and patient usability challenges
• 43:00 – “Reasonably foreseeable misuse” and how to interpret guidance
• 49:05 – Do you design for the lowest common denominator?
• 56:10 – Representing diverse user populations in usability testing
• 1:01:45 – Can a device launch OTC first? The case for wellness-to-Rx strategies
• 1:08:15 – FDA’s perspective on device safety: OTC vs. Rx

Quotes

“The best regulatory professionals don’t just know the rules—they know the exceptions.”

Dr. Mike Drues reminds us that exceptional regulatory strategy lies in understanding nuance, especially in OTC classifications where edge cases can redefine categories.

“Just because a device is used at home doesn’t mean it’s over the counter.”

This insight challenges a common industry assumption, underscoring the importance of carefully defining intended use and environment early in development.

Key Takeaways

1. OTC ≠ Low Risk by Default – Many Class II and even rare Class III devices can be OTC; it’s more about intended user, use environment, and risk mitigation than class alone.
2. Label Expansion Requires Strategy – Transitioning a device from prescription to OTC isn’t just about removing a doctor’s role—it may involve new usability studies, labeling changes, and potentially a 510(k) or de novo submission.
3. Understand the "Intended Use Environment" – FDA doesn’t just care about where the device is used, but how those environmental parameters (like light, humidity, and user training) affect safe operation.
4. Usability Testing Must Reflect Real Users – For OTC devices, human factors validation must account for diverse educational backgrounds, not just ideal users.
5. Don't Rely on Labels Alone – Whether or not users read (or understand) instructions must be tested, not assumed. Intuitive design is critical for OTC success.

References & Resources

• Etienne Nichols on LinkedIn
• Greenlight Guru Medical Device Classification Webinar with Mike Drues (for explanation on device classes)
• FDA Guidance: “Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications”

MedTech 101: OTC vs Prescription Devices

Analogy: Think of a medical device like a power tool. A prescription device is like a chainsaw—powerful, but risky if misused, so it’s only operated by trained professionals. An OTC device is like a screwdriver—still a tool, still regulated, but safe and intuitive enough for the average person to use correctly at home.

Audience Engagement Prompt

Poll Question:

Do you think OTC medical devices should require a minimum standard of in-store or digital education before purchase?

Engagement Prompt:

Have you ever worked on a product that made the switch from prescription to OTC? What surprised you most about the process? Share your story with us at podcast@greenlight.guru.

Feedback Call-to-Action

Enjoyed this episode? Help us keep the conversation going:

• Rate & review us on your favorite podcast platform
• Got a topic suggestion or question? Email us at: podcast@greenlight.guru
• We read every email and may feature your question in a future episode.

Sponsor Mention

This episode is powered by Greenlight Guru, the only QMS platform designed specifically for MedTech companies. Whether you’re launching an OTC wellness device or navigating a PMA, Greenlight Guru helps ensure compliance and accelerate innovation. Learn more at www.greenlight.guru.

They unpack the roles, regulations, and realities of medical device development in a heavily regulated space. From defining what actually counts as a medical device to navigating FDA classifications and global regulations, the trio offers practical insights, industry analogies, and personal war stories that make this episode as entertaining as it is educational. Whether you’re in R&D, marketing, clinical, or quality, this is the episode to bookmark and share with every new hire.

Key Timestamps

02:20 – What counts as a medical device? Intended use and labeling

06:48 – Differentiating roles: Quality, Regulatory, Clinical, R&D, and Marketing

15:40 – Understanding regulatory bodies: FDA, EU MDR, Health Canada, and more

20:15 – FDA Classifications: Class I, II, III, and what determines risk

26:00 – Standards to know: ISO 13485, 14971, 14155, 21 CFR Part 820

33:05 – FDA pathways: 510(k), De Novo, PMA – when and why they apply

41:55 – The design control matrix explained (User Needs through Validation)

49:00 – Reverse engineering design controls: pitfalls and best practices

55:30 – Clinical trials vs. preclinical studies: When each is required

1:00:45 – Manufacturing & supplier controls: operations meets compliance

1:04:15 – Final advice for MedTech newcomers: Read the regs and know the problem

Quotes

“Just because you don’t call it a medical device doesn’t mean the FDA agrees with you.” – Sarah Adams

This quote highlights a key regulatory pitfall: your marketing claims, not just your label, determine if the FDA considers your product a medical device.

“A 510(k) is like someone checking your wristband at the door—you’re cleared to go in. A PMA? That’s a locked door and you need full approval to enter.” – Chris Rush

A memorable analogy that demystifies the difference between FDA clearance and approval pathways.

Top Takeaways

Labeling + Intended Use = Regulatory Trigger

Whether it’s software or a simple tool, if your product makes medical claims or supports medical decision-making, it may fall under FDA or other international regulatory oversight.

Regulatory Pathways Are Tied to Risk and Novelty

Know the difference between a 510(k), De Novo, and PMA. Class II “me-too” devices may avoid clinical trials, while Class III and novel devices usually require significant evidence.

Understand Design Controls Early

Reverse-engineering documentation late in development is risky and inefficient. Start early with user needs and build forward through the five pillars: inputs, outputs, verification, and validation.

Cross-functional Understanding Prevents Compliance Gaps

Marketing, clinical, and R&D all influence regulatory standing. Even social media likes can trigger off-label scrutiny—every department needs to understand their regulatory impact.

Reading Regulations Is Not Optional

A strong regulatory foundation is key to faster development, better audits, and smoother market access. Resources like 21 CFR Part 820 and ISO 13485 are surprisingly readable and essential.

References & Resources

• Etienne Nichols on LinkedIn
• Chris Rush on LinkedIn
• Sara Adams on LinkedIn

MedTech 101: Key Concepts Explained

Design Controls = Your Blueprint for Safe Innovation

Think of design controls as a recipe:

• User Needs = what the customer is hungry for
• Design Inputs = what you plan to give the customer
• Design Outputs = the finished dish (specs)
• Verification = checking the dish matches the recipe
• Validation = confirming the customer loves it

FDA Classes: Think Risk Levels

• Class I – Low risk: toothbrushes, bandages
• Class II – Moderate risk: catheters, infusion pumps (often 510(k))
• Class III – High risk: pacemakers, implants (typically PMA)

510(k) vs. De Novo vs. PMA – Simplified

• 510(k) – You’re like someone else
• De Novo – You’re new, but not high-risk
• PMA – You’re new and high-risk = prove everything

Audience Engagement

Poll Question:

Where do you currently need the most clarity in the medical device development process?

• Understanding FDA classification
• Clinical evidence and trial design
• Design control implementation
• Global regulatory expansion
• Post-market surveillance

Discussion Prompt:

What’s the most surprising thing you’ve learned about medical device regulation that you wish you knew sooner? Share your stories with us at podcast@greenlight.guru.

Feedback & Reviews

If this episode helped demystify the MedTech industry for you or someone on your team, we’d love to hear about it. Share your feedback, topic ideas, or guest suggestions at podcast@greenlight.guru. We read and reply to every message.

Sponsor Message

This episode is brought to you by Greenlight Guru, the only QMS purpose-built for the medical device industry. From design controls to post-market surveillance, our platform helps you stay audit-ready and accelerate product development with confidence. Learn more at www.greenlight.guru.